

REFINITIV

## DELTA REPORT

### 10-Q

SEM - SELECT MEDICAL HOLDINGS C

10-Q - MARCH 31, 2024 COMPARED TO 10-Q - SEPTEMBER 30, 2023

The following comparison report has been automatically generated

TOTAL DELTAS 729

 CHANGES 274

 DELETIONS 265

 ADDITIONS 190

UNITED STATES  
SECURITIES AND EXCHANGE COMMISSION  
Washington, D.C. 20549  
FORM 10-Q

(Mark One)

QUARTERLY REPORT PURSUANT TO SECTION 13 or 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the Quarterly Period Ended **September 30, 2023** **March 31, 2024**

OR

TRANSITION REPORT PURSUANT TO SECTION 13 or 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the transition period from \_\_\_\_\_ to \_\_\_\_\_  
Commission file numbers: 001-34465

**SELECT MEDICAL HOLDINGS CORPORATION**

(Exact name of Registrant as specified in its Charter)

Delaware

20-1764048

(State or Other Jurisdiction of Incorporation or Organization)

(I.R.S. Employer Identification Number)

4714 Gettysburg Road, P.O. Box 2034  
Mechanicsburg, PA 17055

(Address of Principal Executive Offices and Zip code)

(717) 972-1100

(Registrant's telephone number, including area code)

Securities registered pursuant to Section 12(b) of the Act:

Title of each class	Trading Symbol(s)	Name of each exchange on which registered
Common Stock, par value \$0.001 per share	SEM	New York Stock Exchange (NYSE)

Indicate by check mark whether the Registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter periods as such Registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes  No

Indicate by check mark whether the Registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the Registrant was required to submit such files). Yes  No

Indicate by check mark whether the Registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of "large accelerated filer," "accelerated filer," "smaller reporting company," and "emerging growth company" in Rule 12b-2 of the Exchange Act. (Check one):

Large accelerated filer	<input checked="" type="checkbox"/>	Accelerated filer	<input type="checkbox"/>
Non-accelerated filer	<input type="checkbox"/>	Smaller reporting company	<input type="checkbox"/>
		Emerging Growth Company	<input type="checkbox"/>

If an emerging growth company, indicate by check mark if the Registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.

Indicate by check mark whether the Registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes  No

As of **October 31, 2023** **April 30, 2024**, Select Medical Holdings Corporation had outstanding **128,213,538** **130,031,562** shares of common stock.

Unless the context indicates otherwise, any reference in this report to "Holdings" refers to Select Medical Holdings Corporation and any reference to "Select" refers to Select Medical Corporation, the wholly owned operating subsidiary of Holdings, and any of Select's subsidiaries. Any reference to "Concentra" refers to Concentra Group Holdings Parent, LLC ("Concentra Group Holdings Parent") and its subsidiaries, including Concentra Inc. References to the "Company," "we," "us," and "our" refer collectively to Holdings, Select, and Concentra.

**TABLE OF CONTENTS**

<u>PART I</u>	<u>FINANCIAL INFORMATION</u>	<u>3</u>
<u>ITEM 1.</u>	<u>CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</u>	
	<u>Condensed consolidated balance sheets</u>	<u>3</u>
	<u>Condensed consolidated statements of operations</u>	<u>4</u>
	<u>Condensed consolidated statements of comprehensive income</u>	<u>5</u>
	<u>Condensed consolidated statements of changes in equity and income</u>	<u>6</u>
	<u>Condensed consolidated statements of cash flows</u>	<u>87</u>
	<u>Notes to condensed consolidated financial statements</u>	<u>98</u>
<u>ITEM 2.</u>	<u>MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS</u>	<u>2118</u>
<u>ITEM 3.</u>	<u>QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK</u>	<u>4133</u>
<u>ITEM 4.</u>	<u>CONTROLS AND PROCEDURES</u>	<u>4133</u>
<u>PART II</u>	<u>OTHER INFORMATION</u>	<u>4234</u>
<u>ITEM 1.</u>	<u>LEGAL PROCEEDINGS</u>	<u>4234</u>
<u>ITEM 1A.</u>	<u>RISK FACTORS</u>	<u>4234</u>
<u>ITEM 2.</u>	<u>UNREGISTERED SALES OF EQUITY SECURITIES AND USE OF PROCEEDS</u>	<u>4234</u>
<u>ITEM 3.</u>	<u>DEFAULTS UPON SENIOR SECURITIES</u>	<u>4234</u>
<u>ITEM 4.</u>	<u>MINE SAFETY DISCLOSURES</u>	<u>4234</u>
<u>ITEM 5.</u>	<u>OTHER INFORMATION</u>	<u>4234</u>
<u>ITEM 6.</u>	<u>EXHIBITS</u>	<u>4335</u>
<u>SIGNATURES</u>		

**PART I: FINANCIAL INFORMATION**

**ITEM 1. CONDENSED CONSOLIDATED FINANCIAL STATEMENTS**

**Select Medical Holdings Corporation**  
**Condensed Consolidated Balance Sheets**  
 (unaudited)  
 (in thousands, except share and per share amounts)

	ASSETS	December 31, 2022	September 30, 2023
Current Assets:			

Cash and cash equivalents	\$	97,906	\$	77,440
Accounts receivable		941,312		944,219
Prepaid income taxes		31,868		22,716
Current portion of interest rate cap contract		74,857		85,896
Other current assets		125,370		145,816
<b>Total Current Assets</b>		<b>1,271,313</b>		<b>1,276,087</b>
Operating lease right-of-use assets		1,169,740		1,180,907
Property and equipment, net		1,001,440		1,006,842
Goodwill		3,484,200		3,504,654
Identifiable intangible assets, net		351,662		336,639
Interest rate cap contract, net of current portion		45,200		—
Other assets		341,738		378,879
<b>Total Assets</b>	<b>\$</b>	<b>7,665,293</b>	<b>\$</b>	<b>7,684,008</b>
<b>LIABILITIES AND EQUITY</b>				
Current Liabilities:				
Overdrafts	\$	31,961	\$	29,994
Current operating lease liabilities		236,784		242,594
Current portion of long-term debt and notes payable		44,351		35,085
Accounts payable		186,729		183,086
Accrued payroll		209,789		210,088
Accrued vacation		150,695		154,655
Accrued interest		29,837		12,044
Accrued other		264,525		297,931
Income taxes payable		480		579
<b>Total Current Liabilities</b>		<b>1,155,151</b>		<b>1,166,056</b>
Non-current operating lease liabilities		1,008,394		1,019,185
Long-term debt, net of current portion		3,835,211		3,695,244
Non-current deferred tax liability		169,793		146,919
Other non-current liabilities		106,137		106,216
<b>Total Liabilities</b>		<b>6,274,686</b>		<b>6,133,620</b>
Commitments and contingencies (Note 13)				
Redeemable non-controlling interests		34,043		26,999
Stockholders' Equity:				
Common stock, \$0.001 par value, 700,000,000 shares authorized, 127,173,871 and 128,287,211 shares issued and outstanding at 2022 and 2023, respectively		127		128
Capital in excess of par		452,183		482,290
Retained earnings		581,010		722,665
Accumulated other comprehensive income		88,602		62,727
<b>Total Stockholders' Equity</b>		<b>1,121,922</b>		<b>1,267,810</b>
Non-controlling interests		234,642		255,579
<b>Total Equity</b>		<b>1,356,564</b>		<b>1,523,389</b>
<b>Total Liabilities and Equity</b>	<b>\$</b>	<b>7,665,293</b>	<b>\$</b>	<b>7,684,008</b>

	December 31, 2023	March 31, 2024
<b>ASSETS</b>		
Current Assets:		
Cash and cash equivalents	\$	84,006
Accounts receivable		940,335
Prepaid income taxes		22,726
Current portion of interest rate cap contract		58,962
Other current assets		151,617

Total Current Assets		1,257,646	1,440,340
Operating lease right-of-use assets		1,188,616	1,176,713
Property and equipment, net		1,023,561	1,024,626
Goodwill		3,513,170	3,517,071
Identifiable intangible assets, net		329,916	324,125
Other assets		376,722	375,388
<b>Total Assets</b>	<b>\$</b>	<b>7,689,631</b>	<b>\$</b>
			<b>7,858,263</b>
<b>LIABILITIES AND EQUITY</b>			
Current Liabilities:			
Overdrafts	\$	30,274	\$ 28,534
Current operating lease liabilities		245,400	245,617
Current portion of long-term debt and notes payable		70,329	60,184
Accounts payable		174,312	163,551
Accrued and other liabilities		728,150	686,491
<b>Total Current Liabilities</b>		<b>1,248,465</b>	<b>1,184,377</b>
Non-current operating lease liabilities		1,025,867	1,015,160
Long-term debt, net of current portion		3,587,675	3,758,631
Non-current deferred tax liability		143,306	133,987
Other non-current liabilities		110,303	100,175
<b>Total Liabilities</b>		<b>6,115,616</b>	<b>6,192,330</b>
Commitments and contingencies (Note 14)			
Redeemable non-controlling interests		26,297	28,290
Stockholders' Equity:			
Common stock, \$0.001 par value, 700,000,000 shares authorized, 128,369,492 and 128,357,832 shares issued and outstanding at 2023 and 2024, respectively		128	128
Capital in excess of par		493,413	505,403
Retained earnings		751,856	830,821
Accumulated other comprehensive income		42,907	30,930
<b>Total Stockholders' Equity</b>		<b>1,288,304</b>	<b>1,367,282</b>
Non-controlling interests		259,414	270,361
<b>Total Equity</b>		<b>1,547,718</b>	<b>1,637,643</b>
<b>Total Liabilities and Equity</b>	<b>\$</b>	<b>7,689,631</b>	<b>\$</b>
			<b>7,858,263</b>

The accompanying notes are an integral part of these condensed consolidated financial statements.

**Select Medical Holdings Corporation**  
**Condensed Consolidated Statements of Operations**  
**(unaudited)**  
**(in thousands, except per share amounts)**

		For the Three Months				For the Nine Months Ended				For the Three Months Ended March 31,			
		Ended September 30,		September 30,		Ended September 30,		September 30,		Ended March 31,		March 31,	
		2022	2023	2022	2023	2022	2023	2022	2023	2022	2023	2023	2024
Revenue	Revenue	\$1,567,794	\$1,665,694	\$4,752,082	\$5,005,202							2023	2024
Costs and expenses:	Costs and expenses:												

Cost of services, exclusive of depreciation and amortization	Cost of services, exclusive of depreciation and amortization	1,393,817	1,442,509	4,191,377	4,284,931
General and administrative	General and administrative	39,491	41,316	114,272	126,103
Depreciation and amortization	Depreciation and amortization	51,459	52,394	153,579	154,758
Total costs and expenses	Total costs and expenses	1,484,767	1,536,219	4,459,228	4,565,792
Other operating income	Other operating income	8,440	485	23,565	1,211
Income from operations	Income from operations	91,467	129,960	316,419	440,621
Other income and expense:	Other income and expense:			Other income and expense:	
Loss on early retirement of debt		—	(14,692)	—	(14,692)
Equity in earnings of unconsolidated subsidiaries					
Equity in earnings of unconsolidated subsidiaries	Equity in earnings of unconsolidated subsidiaries	8,084	11,561	19,648	30,618
Interest expense					
Interest expense	Interest expense	(45,204)	(50,271)	(121,770)	(147,839)
Income before income taxes	Income before income taxes	54,347	76,558	214,297	308,708
Income tax expense	Income tax expense	16,221	15,742	53,983	70,775
Net income	Net income	38,126	60,816	160,314	237,933
Less: Net income attributable to non-controlling interests	Less: Net income attributable to non-controlling interests	10,960	12,636	28,824	40,711
Net income attributable to Select Medical Holdings Corporation	Net income attributable to Select Medical Holdings Corporation	\$ 27,166	\$ 48,180	\$ 131,490	\$ 197,222
Earnings per common share (Note 12):					
Earnings per common share (Note 13):				Earnings per common share (Note 13):	
Basic and diluted	Basic and diluted	\$ 0.21	\$ 0.38	\$ 1.01	\$ 1.55

The accompanying notes are an integral part of these condensed consolidated financial statements.

**Select Medical Holdings Corporation**  
**Condensed Consolidated Statements of Comprehensive Income**  
(unaudited)  
(in thousands)

	For the Three Months Ended September 30,		For the Nine Months Ended September 30,		
	2022	2023	2022	2023	
<b>For the Three Months Ended March 31,</b>					
<b>For the Three Months Ended March 31,</b>					
<b>For the Three Months Ended March 31,</b>					
2023					2024
Net income	Net income	\$38,126	\$60,816	\$160,314	\$237,933
Other comprehensive income (loss), net of tax:					
Gain on interest rate cap contract	31,079	3,895	82,726	18,726	
Other comprehensive loss, net of tax:					
Gain (loss) on interest rate cap contract					
Gain (loss) on interest rate cap contract					
Gain (loss) on interest rate cap contract					
Reclassification adjustment for gains included in net income	Reclassification adjustment for gains included in net income	(4,485)	(16,215)	(4,452)	(44,601)
Net change, net of tax benefit (expense) of \$(8,865), \$3,998, \$(26,092), and \$8,397		26,594	(12,320)	78,274	(25,875)
Net change, net of tax benefit of \$5,175, and \$3,782					
Comprehensive income	Comprehensive income	64,720	48,496	238,588	212,058
Less:	Less:				
Comprehensive income attributable to non-controlling interests	Comprehensive income attributable to non-controlling interests	10,960	12,636	28,824	40,711
Comprehensive income attributable to Select Medical Holdings Corporation	Comprehensive income attributable to Select Medical Holdings Corporation	\$53,760	\$35,860	\$209,764	\$171,347

*The accompanying notes are an integral part of these condensed consolidated financial statements.*

**Select Medical Holdings Corporation**  
**Condensed Consolidated Statements of Changes in Equity and Income**  
 (unaudited)  
 (in thousands)

For the Nine Months Ended September 30, 2023										
Total Stockholders' Equity										
	Common Stock Issued	Common Stock Par Value	Capital in Excess of Par	Retained Earnings	Accumulated Other Comprehensive Income	Total Stockholders' Equity	Non-controlling Interests	Total Equity		
Balance at December 31, 2022	127,173	\$ 127	452,183	\$ 581,010	\$ 88,602	\$ 1,121,922	\$ 234,642	\$	1,356,564	
Net income attributable to Select Medical Holdings Corporation				70,805		70,805			70,805	
Net income attributable to non-controlling interests						—	12,811		12,811	
Cash dividends declared for common stockholders (\$0.125 per share)				(15,897)		(15,897)			(15,897)	
Issuance of restricted stock	3	0	0			—	—		—	
Vesting of restricted stock			10,003			10,003			10,003	
Issuance of non-controlling interests						—	2,731		2,731	
Non-controlling interests acquired in business combination						—	3,877		3,877	
Distributions to and purchases of non-controlling interests						—	(6,069)		(6,069)	
Redemption value adjustment on non-controlling interests				(436)		(436)			(436)	
Other comprehensive income (loss)					(15,948)	(15,948)			(15,948)	
Other			(1)	1		—	—		—	
Balance at March 31, 2023	127,176	\$ 127	462,185	\$ 635,483	\$ 72,654	\$ 1,170,449	\$ 247,992	\$	1,418,441	
Net income attributable to Select Medical Holdings Corporation				78,237		78,237			78,237	
Net income attributable to non-controlling interests						—	11,539		11,539	
Cash dividends declared for common stockholders (\$0.125 per share)				(15,924)		(15,924)			(15,924)	
Issuance of restricted stock	261	0	0			—	—		—	
Vesting of restricted stock			10,326			10,326			10,326	
Repurchase of common shares	(49)	0	(634)	(872)		(1,506)			(1,506)	
Issuance of non-controlling interests			1,870			1,870	10,211		12,081	
Distributions to and purchases of non-controlling interests			195			195	(14,201)		(14,006)	
Redemption value adjustment on non-controlling interests				(2)		(2)			(2)	
Other comprehensive income					2,393	2,393			2,393	
Balance at June 30, 2023	127,388	\$ 127	473,942	\$ 696,922	\$ 75,047	\$ 1,246,038	\$ 255,541	\$	1,501,579	
Net income attributable to Select Medical Holdings Corporation				48,180		48,180			48,180	
Net income attributable to non-controlling interests						—	10,316		10,316	
Cash dividends declared for common stockholders (\$0.125 per share)				(16,035)		(16,035)			(16,035)	
Issuance of restricted stock	1,217	1	(1)			—	—		—	
Vesting of restricted stock			11,483			11,483			11,483	
Repurchase of common shares	(318)	0	(3,866)	(5,678)		(9,544)			(9,544)	
Issuance of non-controlling interests						—	5,651		5,651	
Non-controlling interests acquired in business combination						—	5,130		5,130	
Distributions to and purchases of non-controlling interests			732	(2,672)		(1,940)	(21,059)		(22,999)	
Redemption value adjustment on non-controlling interests				1,912		1,912			1,912	
Other comprehensive income					(12,320)	(12,320)			(12,320)	
Other				36		36			36	

Balance at September 30, 2023	128,287	\$ 128	482,290	\$ 722,665	\$ 62,727	1,267,810	\$ 255,579	\$ 1,523,389
-------------------------------	---------	--------	---------	------------	-----------	-----------	------------	--------------

*The accompanying notes are an integral part of these condensed consolidated financial statements.*

*For the Three Months Ended March 31, 2024*

	Total Stockholders' Equity							
	Common Stock Issued	Common Stock Par Value	Capital in Excess of Par	Retained Earnings	Accumulated Other Comprehensive Income	Total Stockholders' Equity	Non-controlling Interests	Total Equity
Balance at December 31, 2023	128,369	\$ 128	\$ 493,413	\$ 751,856	\$ 42,907	\$ 1,288,304	\$ 259,414	\$ 1,547,718
Net income attributable to Select Medical Holdings Corporation				96,897		96,897		96,897
Net income attributable to non-controlling interests						—	17,845	17,845
Cash dividends declared for common stockholders (\$0.125 per share)				(16,045)		(16,045)		(16,045)
Issuance of restricted stock	1	0	0			—		—
Forfeitures of unvested restricted stock	(12)	0	0	14		14		14
Vesting of restricted stock			11,596			11,596		11,596
Issuance of non-controlling interests						—	4,002	4,002
Distributions to and purchases of non-controlling interests			394			394	(10,900)	(10,506)
Redemption value adjustment on non-controlling interests				(1,901)		(1,901)		(1,901)
Other comprehensive loss					(11,977)	(11,977)		(11,977)
Balance at March 31, 2024	128,358	\$ 128	\$ 505,403	\$ 830,821	\$ 30,930	\$ 1,367,282	\$ 270,361	\$ 1,637,643

*For the Three Months Ended March 31, 2023*

	Total Stockholders' Equity							
	Common Stock Issued	Common Stock Par Value	Capital in Excess of Par	Retained Earnings	Accumulated Other Comprehensive Income	Total Stockholders' Equity	Non-controlling Interests	Total Equity
Balance at December 31, 2022	127,173	\$ 127	\$ 452,183	\$ 581,010	\$ 88,602	\$ 1,121,922	\$ 234,642	\$ 1,356,564
Net income attributable to Select Medical Holdings Corporation				70,805		70,805		70,805
Net income attributable to non-controlling interests						—	12,811	12,811
Cash dividends declared for common stockholders (\$0.125 per share)				(15,897)		(15,897)		(15,897)
Issuance of restricted stock	3	0	0			—		—
Vesting of restricted stock			10,003			10,003		10,003
Issuance of non-controlling interests						—	2,731	2,731
Non-controlling interests acquired in business combination						—	3,877	3,877
Distributions to and purchases of non-controlling interests						—	(6,069)	(6,069)
Redemption value adjustment on non-controlling interests				(436)		(436)		(436)
Other comprehensive loss					(15,948)	(15,948)		(15,948)
Other			(1)	1		—		—
Balance at March 31, 2023	127,176	\$ 127	\$ 462,185	\$ 635,483	\$ 72,654	\$ 1,170,449	\$ 247,992	\$ 1,418,441

*For the Nine Months Ended September 30, 2022*

	Total Stockholders' Equity							
	Common Stock Issued	Common Stock Par Value	Capital in Excess of Par	Retained Earnings	Accumulated Other Comprehensive Income	Total Stockholders' Equity	Non-controlling Interests	Total Equity
Balance at December 31, 2021	133,884	\$ 134	\$ 504,314	\$ 593,251	\$ 12,282	\$ 1,109,981	\$ 215,921	\$ 1,325,902
Net income attributable to Select Medical Holdings Corporation				49,117		49,117		49,117
Net income attributable to non-controlling interests						—	4,891	4,891
Cash dividends declared for common stockholders (\$0.125 per share)				(16,691)		(16,691)		(16,691)
Issuance of restricted stock	13	0	0			—		—
Vesting of restricted stock			8,288			8,288		8,288

Repurchase of common shares	(2,128)	(2)	(23,459)	(28,215)	(51,676)	(51,676)
Issuance of non-controlling interests			651		651	4,578
Non-controlling interests acquired in business combination, measurement period adjustment				—	12,463	12,463
Distributions to and purchases of non-controlling interests				—	(9,097)	(9,097)
Redemption value adjustment on non-controlling interests			(1,381)		(1,381)	(1,381)
Other comprehensive income				39,853	39,853	39,853
Other			(2)		(2)	(2)
Balance at March 31, 2022	131,769	\$ 132	489,794	\$ 596,079	\$ 52,135	\$ 1,138,140
Net income attributable to Select Medical Holdings					228,756	\$ 1,366,896
Corporation				55,207		55,207
Net income attributable to non-controlling interests					—	9,155
Cash dividends declared for common stockholders (\$0.125 per share)			(16,108)		(16,108)	(16,108)
Issuance of restricted stock	211	0	0		—	—
Forfeitures of unvested restricted stock	(6)	0	0	3		3
Vesting of restricted stock			8,406		8,406	8,406
Repurchase of common shares	(5,483)	(6)	(56,965)	(69,976)		(126,947)
Issuance of non-controlling interests					—	1,725
Distributions to and purchases of non-controlling interests			534		534	(7,348)
Redemption value adjustment on non-controlling interests				355		355
Other comprehensive loss				11,827	11,827	11,827
Other			(4)		(4)	(4)
Balance at June 30, 2022	126,491	\$ 126	441,769	\$ 565,556	\$ 63,962	\$ 1,071,413
Net income attributable to Select Medical Holdings					232,288	\$ 1,303,701
Corporation				27,166		27,166
Net income attributable to non-controlling interests					—	8,720
Cash dividends declared for common stockholders (\$0.125 per share)			(15,893)		(15,893)	(15,893)
Issuance of restricted stock	1,228	1	(1)		—	—
Forfeitures of unvested restricted stock	(6)	0	0	3		3
Vesting of restricted stock			9,649		9,649	9,649
Repurchase of common shares	(569)	0	(6,574)	(8,417)		(14,991)
Issuance of non-controlling interests					—	142
Distributions to and purchases of non-controlling interests			(2,450)		(2,450)	(12,226)
Redemption value adjustment on non-controlling interests			4,108		4,108	4,108
Other comprehensive loss				26,594	26,594	26,594
Other			(4)		(4)	(4)
Balance at September 30, 2022	127,144	\$ 127	444,843	\$ 570,069	\$ 90,556	\$ 1,105,595
					228,924	\$ 1,334,519

The accompanying notes are an integral part of these condensed consolidated financial statements.

**Select Medical Holdings Corporation**  
**Condensed Consolidated Statements of Cash Flows**  
 (unaudited)  
 (in thousands)

Operating activities	Operating activities	For the Nine Months Ended September 30,		For the Three Months Ended March 31,	
		2022	2023	2023	2024
Operating activities					
Net income	Net income	\$ 160,314	\$ 237,933		

Adjustments to reconcile net income to net cash provided by operating activities:

Adjustments to reconcile net income to net cash provided by (used in) operating activities:

Distributions from unconsolidated subsidiaries	Distributions from unconsolidated subsidiaries	16,892	9,896
Depreciation and amortization	Depreciation and amortization	153,579	154,758
Provision for expected credit losses	Provision for expected credit losses	(41)	1,101
Equity in earnings of unconsolidated subsidiaries	Equity in earnings of unconsolidated subsidiaries	(19,648)	(30,618)
Loss on extinguishment of debt		—	175
Gain on sale or disposal of assets		(1,593)	(7)

(Gain) loss on sale or disposal of assets

(Gain) loss on sale or disposal of assets

(Gain) loss on sale or disposal of assets

Stock compensation expense	Stock compensation expense	27,956	31,991
Amortization of debt discount, premium and issuance costs		1,696	1,899
Amortization of debt discount, premium, and issuance costs			

Deferred income taxes	Deferred income taxes	(7,080)	(17,049)
-----------------------	-----------------------	---------	----------

Changes in operating assets and liabilities, net of effects of business combinations:	Changes in operating assets and liabilities, net of effects of business combinations:
---	---

Accounts receivable	Accounts receivable	(19,686)	(3,014)
Other current assets	Other current assets	2,923	(17,276)

Changes in operating assets and liabilities, net of effects of business combinations:

Other assets	Other assets	9,650	7,028
Accounts payable	Accounts payable	(22,185)	4,788
Accrued expenses	Accrued expenses	52,352	21,011
Government advances		(82,848)	—
Net cash provided by operating activities		272,281	402,616
Net cash provided by (used in) operating activities			
Net cash provided by (used in) operating activities			
Net cash provided by (used in) operating activities			
<b>Investing activities</b>	<b>Investing activities</b>		
Business combinations, net of cash acquired	Business combinations, net of cash acquired	(22,027)	(20,482)
Purchases of property, equipment, and other assets	Purchases of property, equipment, and other assets	(135,119)	(168,597)
Investment in businesses	Investment in businesses	(17,323)	(9,874)
Proceeds from sale of assets		5,364	60
Proceeds from sale of assets and businesses			
Net cash used in investing activities	Net cash used in investing activities	(169,105)	(198,893)
<b>Financing activities</b>	<b>Financing activities</b>		
Borrowings on revolving facilities	Borrowings on revolving facilities	845,000	635,000
Payments on revolving facilities	Payments on revolving facilities	(625,000)	(740,000)
Proceeds from term loans		—	2,092,232
Payments on term loans			
Payments on term loans			
Payments on term loans	Payments on term loans	—	(2,108,694)
Borrowings of other debt	Borrowings of other debt	20,866	30,849
Borrowings of other debt			
Borrowings of other debt			
Principal payments on other debt	Principal payments on other debt	(25,165)	(38,298)

Dividends paid to common stockholders	Dividends paid to common stockholders	(48,692)	(47,856)
Repurchase of common stock		(193,614)	(11,050)
Decrease in overdrafts			
Decrease in overdrafts			
Decrease in overdrafts	Decrease in overdrafts	(9,091)	(1,967)
Proceeds from issuance of non-controlling interests	Proceeds from issuance of non-controlling interests	7,096	20,463
Distributions to and purchases of non-controlling interests	Distributions to and purchases of non-controlling interests	(40,663)	(54,868)
Net cash used in financing activities		(69,263)	(224,189)
Net cash provided by financing activities			
Net cash provided by financing activities			
Net cash provided by financing activities			
Net increase (decrease) in cash and cash equivalents	Net increase (decrease) in cash and cash equivalents	33,913	(20,466)
Cash and cash equivalents at beginning of period	Cash and cash equivalents at beginning of period	74,310	97,906
Cash and cash equivalents at end of period	Cash and cash equivalents at end of period	\$108,223	\$ 77,440
Supplemental information	Supplemental information	Supplemental information	
Cash paid for interest, excluding amounts received of \$6,232 and \$60,353 under the interest rate cap contract		\$143,455	\$ 221,697
Cash paid for interest, excluding amounts received of \$17,828 and \$22,515 under the interest rate cap contract			
Cash paid for taxes	Cash paid for taxes	24,844	78,502

The accompanying notes are an integral part of these condensed consolidated financial statements.

**SELECT MEDICAL HOLDINGS CORPORATION**  
**NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (UNAUDITED)**

## 1. Basis of Presentation

The unaudited condensed consolidated financial statements of Select Medical Holdings Corporation ("Holdings") include the accounts of its wholly owned subsidiary, Select Medical Corporation ("Select"). Holdings conducts substantially all of its business through Select and its subsidiaries. Holdings, Select, and Select's subsidiaries are collectively referred to as the "Company." The unaudited condensed consolidated financial statements of the Company as of **September 30, 2023** **March 31, 2024**, and for the three and nine month periods ended **September 30, 2022** **March 31, 2023** and **2023, 2024**, have been prepared pursuant to the rules and regulations of the Securities and Exchange Commission (the "SEC") for interim reporting and the accounting principles generally accepted in the United States of America ("GAAP"). Accordingly, certain information and disclosures required by GAAP, which are normally included in the notes to the consolidated financial statements, have been condensed or omitted pursuant to those rules and regulations, although the Company believes the disclosure is adequate to make the information presented not misleading. In the opinion of management, such information contains all adjustments, which are normal and recurring in nature, necessary for a fair statement of the financial position, results of operations and cash flow for such periods. All significant intercompany transactions and balances have been eliminated.

The results of operations for the three and nine months ended **September 30, 2023** **March 31, 2024**, are not necessarily indicative of the results to be expected for the full fiscal year ending **December 31, 2023** **December 31, 2024**. These unaudited condensed consolidated financial statements should be read in conjunction with the consolidated financial statements and notes thereto for the year ended **December 31, 2022** **December 31, 2023**, contained in the Company's Annual Report on Form 10-K filed with the SEC on **February 23, 2023** **February 22, 2024**.

## 2. Accounting Policies

### Recent Accounting Guidance Not Yet Adopted

#### Segment Reporting

In November 2023, FASB issued ASU 2023-07, *Segment Reporting (Topic 280): Improvements to Reportable Segment Disclosures*, which is intended to improve disclosure of segment information so that investors can better understand an entity's overall performance. The ASU requires entities to quantitatively disclose significant segment expenses that are regularly provided to the chief operating decision maker for each reportable segment, as well as the amount of other segment items for each reportable segment and a description of what the other segment items are comprised. Disclosure of multiple measures of profit or loss will be permitted by the ASU.

The ASU is effective for annual reporting periods beginning on or after December 15, 2023, and interim periods with fiscal years beginning after December 15, 2024; however, early adoption is permitted. The ASU is required to be applied retrospectively to all periods presented in the financial statements. The Company is currently reviewing the impact that ASU 2023-07 will have on the disclosures in our consolidated financial statements.

#### Income Taxes

In December 2023, FASB issued ASU 2023-09, *Income Taxes (Topic 740): Improvements to Income Tax Disclosures*, which is intended to improve the transparency and decision usefulness of income tax disclosures. The ASU includes enhanced requirements on the rate reconciliation, including specific categories that must be disclosed, and provides a threshold over which reconciling items must be disclosed. The amendments in the update also require annual disclosure of income taxes paid, disaggregated by federal, state, and foreign taxes, as well as any individual jurisdictions in which income taxes paid is greater than 5% of total income taxes paid.

The ASU is effective for annual periods beginning after December 15, 2024; however early adoption is permitted. The ASU can be applied either prospectively or retrospectively. The Company is currently reviewing the impact that ASU 2023-09 will have to the disclosures in our consolidated financial statements.

### Recently Adopted Accounting Guidance

#### Leases

In March 2023, the Financial Accounting Standards Board ("FASB") issued Accounting Standards Update ("ASU") 2023-01, *Leases (Topic 842): Common Control Arrangements*, which requires companies to amortize leasehold improvements associated with related party leases under common control over the useful life of the leasehold improvement to the common control group. The ASU is effective for annual reporting periods beginning on or after December 15, 2023; however, early adoption is permitted. The ASU can either be applied prospectively or retrospectively.

The Company is currently evaluating adopted this ASU, but does not expect it to have a material impact on its consolidated financial statements upon adoption. The Company plans to adopt the ASU using the prospective method as of transition on January 1, 2024. There was not a material impact on the Company's consolidated financial statements upon adoption.

#### Use of Estimates

The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets, liabilities, revenues, and expenses. Actual results could differ from those estimates.

## 3. Credit Risk Concentrations

Financial instruments that potentially subject the Company to concentrations of credit risk consist primarily of cash balances and accounts receivable. The Company's excess cash is held with large financial institutions. The Company grants unsecured credit to its patients, most of whom reside in the service area of the Company's facilities and are insured under third-party payor agreements.

Because of the diversity in the Company's non-governmental third-party payor base, as well as their geographic dispersion, accounts receivable due from the Medicare program represent the Company's only significant concentration of credit risk. Approximately **19% 17%** and **15% 20%** of the Company's accounts receivable is due from Medicare at both **December 31, 2022** **December 31, 2023**, and **September 30, 2023** **March 31, 2024**, respectively.

#### 4. Redeemable Non-Controlling Interests

The ownership interests held by outside parties in subsidiaries, which include limited liability companies and limited partnerships, controlled by the Company are classified as non-controlling interests. Some of the Company's non-controlling ownership interests consist of outside parties that have certain redemption rights that, if exercised, require the Company to purchase the parties' ownership interests. These interests are classified and reported as redeemable non-controlling interests and have been adjusted to their approximate redemption values, after the attribution of net income or loss.

The changes in redeemable non-controlling interests are as follows:

	Three Months Ended March 31, 2023	2023	Three Months Ended March 31, 2024
			(in thousands)
Balance as of January 1			
Net income attributable to redeemable non- controlling interests			
Distributions to redeemable non- controlling interests			
Distributions to redeemable non- controlling interests			
Distributions to redeemable non- controlling interests			
Redemption value adjustment on redeemable non- controlling interests			

Redemption value adjustment on redeemable non-controlling interests		
Redemption value adjustment on redeemable non-controlling interests		
Other		
Balance as of		
March 31		
	<b>Nine Months Ended</b>	
	<b>September 30,</b>	
	<b>2022</b>	<b>2023</b>
	(in thousands)	
Balance as of		
January 1	\$ 39,033	\$34,043
Net income attributable to redeemable non-controlling interests	1,918	1,641
Distributions to redeemable non-controlling interests	(1,198)	(1,900)
Redemption value adjustment on redeemable non-controlling interests	1,381	436
Other	536	179
Balance as of		
March 31	\$ 41,670	\$34,399
Net income attributable to redeemable non-controlling interests	1,900	2,084

Distributions to and purchases of redeemable non- controlling interests	(1,553)	(2,110)
Redemption value adjustment on redeemable non- controlling interests	(355)	2
Other	535	—
Balance as of June 30	\$ 42,197	\$34,375
Net income attributable to redeemable non- controlling interests	2,240	2,320
Distributions to and purchases of redeemable non- controlling interests	(7,325)	(7,784)
Redemption value adjustment on redeemable non- controlling interests	(4,108)	(1,912)
Other	536	—
Balance as of September 30	\$ 33,540	\$26,999

##### 5. Variable Interest Entities

Certain states prohibit the "corporate practice of medicine," which restricts the Company from owning medical practices which directly employ physicians or therapists and from exercising control over medical decisions by physicians and therapists. In these states, the Company enters into long-term management agreements with medical practices that are owned by licensed physicians or therapists, which, in turn, employ or contract with physicians or therapists who provide professional medical services. The management agreements provide for the Company to direct the transfer of ownership of the medical practices. Based on the provisions of the management agreements, the medical practices are variable interest entities for which the Company is the primary beneficiary.

As of December 31, 2022 December 31, 2023, and September 30, 2023 March 31, 2024, the total assets of the Company's variable interest entities were \$232.1 million \$246.4 million and \$273.4 million \$263.7 million, respectively, and are principally comprised of accounts receivable. As of December 31, 2022 December 31, 2023, and September 30, 2023 March 31, 2024, the total liabilities of the Company's variable interest entities were \$78.8 million \$84.3 million and \$85.8 million \$85.4 million, respectively, and are principally comprised of accounts payable and accrued expenses. These variable interest entities have obligations payable for services received under their management agreements with the Company of \$158.3 million \$161.8 million and \$195.1 million \$179.5 million as of December 31, 2022 December 31, 2023, and September 30, 2023 March 31, 2024, respectively. These intercompany balances are eliminated in consolidation.

## 6. Leases

The Company's total lease cost is as follows:

	Three Months Ended September 30, 2022					Three Months Ended September 30, 2023				
	Unrelated Parties		Related Parties		Total	Unrelated Parties		Related Parties		Total
	(in thousands)					(in thousands)				
Operating lease cost	\$ 73,795	\$ 1,810	\$ 75,605	\$ 78,147	\$ 1,834	\$ 79,981				
Finance lease cost:										
Amortization of right-of-use assets	381	—	381	387	—	387				
Interest on lease liabilities	335	—	335	352	—	352				
Short-term lease cost	24	—	24	—	—	—				
Variable lease cost	14,855	141	14,996	16,562	—	16,562				
Sublease income	(1,963)	—	(1,963)	(1,633)	—	(1,633)				
Total lease cost	\$ 87,427	\$ 1,951	\$ 89,378	\$ 93,815	\$ 1,834	\$ 95,649				
Nine Months Ended										
September 30, 2022			September 30, 2023							
Unrelated	Related		Unrelated	Related						
Parties	Parties	Total	Parties	Parties	Total					
(in thousands)										
Three Months Ended March 31, 2023										
						2023		2024		
						Unrelated	Related	Unrelated	Related	Total
						Parties	Parties	Parties	Parties	Total
(in thousands)										
Operating lease cost	Operating lease cost	\$ 221,726	\$ 5,428	\$ 227,154	\$ 231,671	\$ 5,501	\$ 237,172			
Finance lease cost:	Finance lease cost:									
Amortization of right-of-use assets	Amortization of right-of-use assets	1,105	—	1,105	1,185	—	1,185			
Amortization of right-of-use assets	Amortization of right-of-use assets									
Amortization of right-of-use assets	Amortization of right-of-use assets									
Interest on lease liabilities	Interest on lease liabilities	1,011	—	1,011	1,059	—	1,059			
Short-term lease cost		74	—	74	—	—	—			
Variable lease cost										
Variable lease cost										
Variable lease cost	Variable lease cost	42,917	321	43,238	48,854	84	48,938			
Sublease income	Sublease income	(5,869)	—	(5,869)	(5,027)	—	(5,027)			
Total lease cost	Total lease cost	\$ 260,964	\$ 5,749	\$ 266,713	\$ 277,742	\$ 5,585	\$ 283,327			

## 7. Long-Term Debt and Notes Payable

As of September 30, 2023 March 31, 2024, the Company's long-term debt and notes payable are as follows:

	Unamortized					Unamortized				
	Principal	Premium	Issuance	Carrying	Fair Value	Principal	Unamortized	Premium	Unamortized	Carrying
	Outstanding	(Discount)	Costs	Value	Fair Value	Outstanding	Unamortized	(Discount)	Issuance Costs	Value
(in thousands)						(in thousands)				
(in thousands)						(in thousands)				

6.250% senior notes	6.250% senior notes	\$ 1,225,000	\$ 17,046	\$ (8,697)	\$ 1,233,349	\$ 1,193,126					
Credit facilities:	Credit facilities:						Credit facilities:				
Revolving facility	Revolving facility	340,000	—	—	340,000	331,500					
Term loan	Term loan	2,097,743	(12,999)	(3,487)	2,081,257	2,087,254					
Other debt, including finance leases	Other debt, including finance leases	75,804	—	(81)	75,723	75,723					
Total debt	Total debt	\$ 3,738,547	\$ 4,047	\$ (12,265)	\$ 3,730,329	\$ 3,687,603					

Principal maturities of the Company's long-term debt and notes payable are approximately as follows:

	2023	2024	2025	2026	2027	Thereafter	Total	2024	2025	2026	2027	2028	Thereafter	Total
(in thousands)														
(in thousands)														
6.250% senior notes	\$ —	\$ —	\$ —	\$ 1,225,000	\$ —	\$ —	\$ 1,225,000							
Credit facilities:								Credit facilities:						
Revolving facility	—	—	—	—	340,000	—	340,000							
Term loan	5,258	21,030	21,030	21,030	2,029,395	—	2,097,743							
Other debt, including finance leases	5,962	50,988	2,527	2,427	1,941	11,959	75,804							
Total debt	\$ 11,220	\$ 72,018	\$ 23,557	\$ 1,248,457	\$ 2,371,336	\$ 11,959	\$ 3,738,547							

As of December 31, 2022 December 31, 2023, the Company's long-term debt and notes payable are as follows:

	Principal Outstanding	Unamortized Premium (Discount)	Unamortized Issuance Costs	Carrying Value	Fair Value
(in thousands)					
6.250% senior notes	\$ 1,225,000	\$ 21,555	\$ (10,948)	\$ 1,235,607	\$ 1,163,689
Credit facilities:					
Revolving facility	445,000	—	—	445,000	443,331
Term loan	2,103,437	(4,376)	(4,771)	2,094,290	2,056,110
Other debt, including finance leases	104,800	—	(135)	104,665	104,665
Total debt	\$ 3,878,237	\$ 17,179	\$ (15,854)	\$ 3,879,562	\$ 3,767,795

#### Select Credit Facilities

On July 31, 2023, the Company entered into Amendment No. 8 to the Select credit agreement. Amendment No. 8 provides for a new tranche of term loans in an aggregate principal amount of \$2,103.0 million to replace the existing term loans and a \$710.0 million new revolving credit facility to replace the \$650.0 million existing revolving credit facility. The term loans and the extended revolving credit facility will mature on March 6, 2027, with an early springing maturity 90 days prior to the senior notes maturity, triggered if more than \$300.0 million of senior notes remain outstanding on May 15, 2026. The term loans have an interest rate of Term SOFR plus 3.00% and the revolving credit facility has an interest rate of Adjusted Term SOFR (which includes a 0.10% credit spread adjustment) plus 2.50%, subject to a leverage-based pricing grid. During the three months ended September 30, 2023, the Company recognized a \$14.7 million loss on early retirement of debt as a result of the amendment to the Select credit agreement.

On August 31, 2023, the Company entered into Amendment No. 9 to the Select credit agreement. Amendment No. 9 increased the revolving credit facility commitments from \$710.0 million to \$770.0 million.

	Principal Outstanding	Unamortized Premium (Discount)	Unamortized Issuance Costs	Carrying Value	Fair Value
(in thousands)					
6.250% senior notes	\$ 1,225,000	\$ 15,533	\$ (7,937)	\$ 1,232,596	\$ 1,228,063
Credit facilities:					
Revolving facility	280,000	—	—	280,000	278,600
Term loan	2,092,485	(12,040)	(3,229)	2,077,216	2,092,485
Other debt, including finance leases	68,255	—	(63)	68,192	68,192
Total debt	\$ 3,665,740	\$ 3,493	\$ (11,229)	\$ 3,658,004	\$ 3,667,340

## 8. Accrued and other liabilities

The following table sets forth the components of accrued and other liabilities on the Condensed Consolidated Balance Sheets:

	December 31, 2023	March 31, 2024
Accrued payroll	\$ 238,768	\$ 184,801
Accrued vacation	157,748	164,113
Accrued interest	32,472	14,438
Accrued other	297,663	292,587
Income taxes payable	1,499	30,552
Accrued and other liabilities	\$ 728,150	\$ 686,491

## 9. Interest Rate Cap

The Company is subject to market risk exposure arising from changes in interest rates on its term loan. The term loan, which bears interest at a variable rate that is indexed to a benchmark which changed from LIBOR to SOFR on May 31, 2023, one-month Term SOFR. The Company's objective in using an interest rate derivative is to mitigate its exposure to increases in interest rates. The interest rate cap limits the Company's exposure to increases in the variable rate index to 1.0% on \$2.0 billion of principal outstanding under the term loan, as the interest rate cap provides for payments from the counterparty when interest rates rise above 1.0%. The interest rate cap has a \$2.0 billion notional amount and is effective through September 30, 2024. The Company will pay a monthly premium for the interest rate cap over the term of the agreement. The annual premium is equal to 0.0916% of the notional amount, or approximately \$1.8 million.

The interest rate cap has been designated as a cash flow hedge and is highly effective at offsetting the changes in cash outflows when the variable rate index exceeds 1.0%. Changes in the fair value of the interest rate cap, net of tax, are recognized in other comprehensive income and are reclassified out of accumulated other comprehensive income and into interest expense when the hedged interest obligations affect earnings.

The following table outlines the changes in accumulated other comprehensive income (loss), net of tax, during the periods presented:

	Three Months Ended March 31, 2023		Three Months Ended March 31, 2024	
			(in thousands)	
Balance as of January 1				
Gain (loss) on interest rate cap cash flow hedge				
Amounts reclassified from accumulated other comprehensive income				
Balance as of March 31				
Nine Months Ended September 30, 2022 2023				
(in thousands)				

Balance as of			
January 1	\$ 12,282	\$ 88,602	
Gain (loss) on interest rate cap cash flow hedge	39,814	(2,696)	
Amounts reclassified from accumulated other comprehensive income	39	(13,252)	
<b>Balance as of</b>			
March 31	\$ 52,135	\$ 72,654	
Gain on interest rate cap cash flow hedge	11,833	17,527	
Amounts reclassified from accumulated other comprehensive income	(6)	(15,134)	
<b>Balance as of</b>			
June 30	\$ 63,962	\$ 75,047	
Gain on interest rate cap cash flow hedge	31,079	3,895	
Amounts reclassified from accumulated other comprehensive income	(4,485)	(16,215)	
<b>Balance as of</b>			
September 30	<u>\$ 90,556</u>	<u>\$ 62,727</u>	

The effects on net income of amounts reclassified from accumulated other comprehensive income are as follows:

Statement of Operations	Statement of Operations	Three Months		Nine Months		Statement of Operations	2023	2024				
		Ended		Ended								
		September 30,	September 30,	September 30,	September 30,							
Three Months												
Ended March 31,												
Three Months												
Ended March 31,												
Three Months												
Ended March 31,												
(in thousands)		(in thousands)										
(in thousands)												
Gains included in interest expense	Gains included in interest expense	\$5,980	\$21,477	\$5,936	\$59,074							
Income tax expense	Income tax expense	(1,495)	(5,262)	(1,484)	(14,473)							

Amounts reclassified from accumulated other comprehensive income	Amounts reclassified from accumulated other comprehensive income	\$4,485	\$16,215	\$4,452	\$44,601
--	--	---------	----------	---------	----------

The Company expects that approximately ~~\$83.0~~ \$40.7 million of estimated pre-tax gains will be reclassified from accumulated other comprehensive income into interest expense ~~within~~ through the next twelve months ~~expirations~~ of the interest rate cap on September 30, 2024.

Refer to Note 9.10 – Fair Value of Financial Instruments for information on the fair value of the Company's interest rate cap contract and its balance sheet classification.

#### 9.10. Fair Value of Financial Instruments

Financial instruments which are measured at fair value, or for which a fair value is disclosed, are classified in the fair value hierarchy, as outlined below, on the basis of the observability of the inputs used in the fair value measurement:

- Level 1 – inputs are based upon quoted prices for identical instruments in active markets.
- Level 2 – inputs are based upon quoted prices for similar instruments in active markets, quoted prices for identical or similar instruments in markets that are not active, and model-based valuation techniques for which all significant inputs are observable in the market or can be corroborated by observable market data.
- Level 3 – inputs are generally unobservable and typically reflect management's estimates of assumptions that market participants would use in pricing the instrument.

The Company's interest rate cap contract is recorded at its fair value in the condensed consolidated balance sheets on a recurring basis. The fair value of the interest rate cap contract is based upon a model-derived valuation using observable market inputs, such as interest rates and interest rate volatility, and the strike price.

Financial Instrument	Financial Instrument	Balance		Financial Instrument	Balance Sheet Classification	Level	December 31, 2023	March 31, 2024
		Sheet	December 31, 2022					
Asset:	Asset:	(in thousands)		Asset:				
Interest rate cap contract, current portion	Interest rate cap contract, current portion	Current portion	interest rate cap contract	Level 2	\$ 74,857	\$ 85,896		
			Interest rate cap contract, non-current portion	Level 2	45,200	—		

The Company does not measure its indebtedness at fair value in its condensed consolidated balance sheets. The fair value of the credit facilities is based on quoted market prices for this debt in the syndicated loan market. The fair value of the senior notes is based on quoted market prices. The carrying value of the Company's other debt, as disclosed in Note 7 – Long-Term Debt and Notes Payable, approximates fair value.

Financial Instrument	Financial Instrument	December 31, 2022			September 30, 2023			Financial Instrument	Balance Sheet Classification	Level	December 31, 2023	March 31, 2024						
		Level	Carrying Value	Carrying Fair Value	Level	Carrying Value	Carrying Fair Value											
		(in thousands)																
		(in thousands)																
6.250% senior notes	6.250% senior notes	Level 2	\$ 1,235,607	\$ 1,163,689	Level 2	\$ 1,233,349	\$ 1,193,126											
Credit facilities:	Credit facilities:																	
Revolving facility	Revolving facility																	
Term loan	Term loan	Level 2	445,000	443,331	Level 2	340,000	331,500											
			2,094,290	2,056,110		2,081,257	2,087,254											

The Company's other financial instruments, which primarily consist of cash and cash equivalents, accounts receivable, and accounts payable, approximate fair value because of the short-term maturities of these instruments.

## 10.11. Segment Information

The Company's reportable segments consist of the critical illness recovery hospital segment, rehabilitation hospital segment, outpatient rehabilitation segment, and Concentra segment. Other activities include the Company's corporate shared services, certain investments, and employee leasing services with non-consolidating subsidiaries.

The Company evaluates the performance of its segments based on Adjusted EBITDA. Adjusted EBITDA is defined as earnings excluding interest, income taxes, depreciation and amortization, gain (loss) on early retirement of debt, stock compensation expense, transaction costs associated with the Concentra separation, gain (loss) on sale of businesses, and equity in earnings (losses) of unconsolidated subsidiaries. The Company has provided additional information regarding its reportable segments, such as total assets, which contributes to the understanding of the Company and provides useful information to the users of the consolidated financial statements.

The following tables summarize selected financial data for the Company's reportable segments.

	Three Months Ended September 30,		Nine Months Ended September 30,	
	2022		2023	
	(in thousands)			
<b>Revenue:</b>				
Critical illness recovery hospital	\$ 524,584	\$ 563,628	\$ 1,672,247	\$ 1,732,645
Rehabilitation hospital	229,387	247,101	678,908	719,419
Outpatient rehabilitation	284,993	291,804	844,191	890,679
Concentra	444,576	473,964	1,309,356	1,397,341
Other	84,254	89,197	247,380	265,118
<b>Total Company</b>	<b>\$ 1,567,794</b>	<b>\$ 1,665,694</b>	<b>\$ 4,752,082</b>	<b>\$ 5,005,202</b>
<b>Adjusted EBITDA:</b>				
Critical illness recovery hospital	\$ 11,013	\$ 46,362	\$ 66,999	\$ 188,631
Rehabilitation hospital	49,772	53,626	141,996	155,531
Outpatient rehabilitation	25,715	26,346	85,912	89,395
Concentra	90,025	98,907	272,101	293,046
Other <sup>(1)</sup>	(23,412)	(31,404)	(69,054)	(99,234)
<b>Total Company</b>	<b>\$ 153,113</b>	<b>\$ 193,837</b>	<b>\$ 497,954</b>	<b>\$ 627,369</b>
<b>Total assets:</b>				
Critical illness recovery hospital	\$ 2,368,968	\$ 2,454,578	\$ 2,368,968	\$ 2,454,578
Rehabilitation hospital	1,189,486	1,222,853	1,189,486	1,222,853
Outpatient rehabilitation	1,377,010	1,401,148	1,377,010	1,401,148
Concentra	2,309,392	2,321,671	2,309,392	2,321,671
Other	310,120	283,758	310,120	283,758
<b>Total Company</b>	<b>\$ 7,554,976</b>	<b>\$ 7,684,008</b>	<b>\$ 7,554,976</b>	<b>\$ 7,684,008</b>
<b>Purchases of property, equipment, and other assets:</b>				
Critical illness recovery hospital	\$ 21,534	\$ 21,098	\$ 60,631	\$ 76,119
Rehabilitation hospital	392	4,813	11,487	15,298
Outpatient rehabilitation	10,098	8,855	28,826	29,263
Concentra	9,074	15,456	28,030	45,702
Other	844	(24)	6,145	2,215
<b>Total Company</b>	<b>\$ 41,942</b>	<b>\$ 50,198</b>	<b>\$ 135,119</b>	<b>\$ 168,597</b>

(1) For the three and nine months ended September 30, 2023, Adjusted EBITDA included other operating income of \$0.5 million.

For the three and nine months ended September 30, 2022, Adjusted EBITDA included other operating income of \$8.1 million and \$23.2 million, respectively. The other operating income was principally related to the recognition of payments received under the Provider Relief Fund for health care related expenses and loss of revenue attributable to COVID-19.

Three Months Ended March 31,

		2023	2024
		(in thousands)	
Revenue:			
Critical illness recovery hospital		\$ 593,926	\$ 655,880
Rehabilitation hospital		231,462	265,700
Outpatient rehabilitation		295,903	303,158
Concentra		456,298	467,598
Other		87,391	96,473
Total Company		\$ 1,664,980	\$ 1,788,809
Adjusted EBITDA:			
Critical illness recovery hospital		\$ 76,773	\$ 115,940
Rehabilitation hospital		47,216	61,400
Outpatient rehabilitation		30,199	24,928
Concentra		93,748	96,142
Other		(33,873)	(36,493)
Total Company		\$ 214,063	\$ 261,917
Total assets:			
Critical illness recovery hospital		\$ 2,507,265	\$ 2,608,979
Rehabilitation hospital		1,203,069	1,233,828
Outpatient rehabilitation		1,397,823	1,423,740
Concentra		2,300,632	2,362,848
Other		290,947	228,868
Total Company		\$ 7,699,736	\$ 7,858,263
Purchases of property, equipment, and other assets:			
Critical illness recovery hospital		\$ 23,658	\$ 15,941
Rehabilitation hospital		8,582	7,101
Outpatient rehabilitation		9,932	9,500
Concentra		14,400	17,231
Other		2,313	2,744
Total Company		\$ 58,885	\$ 52,517

A reconciliation of Adjusted EBITDA to income before income taxes is as follows:

	Three Months Ended March 31, 2023					
	Critical Illness Recovery Hospital	Rehabilitation Hospital	Outpatient Rehabilitation	Concentra	Other	Total
	(in thousands)					
Adjusted EBITDA	\$ 76,773	\$ 47,216	\$ 30,199	\$ 93,748	\$ (33,873)	
Depreciation and amortization	(16,637)	(6,888)	(8,457)	(18,310)	(2,133)	
Stock compensation expense	—	—	—	(178)	(10,003)	
Income (loss) from operations	\$ 60,136	\$ 40,328	\$ 21,742	\$ 75,260	\$ (46,009)	\$ 151,457
Equity in earnings of unconsolidated subsidiaries						8,556
Interest expense						(48,571)
Income before income taxes						\$ 111,442

Three Months Ended September 30, 2022						Three Months Ended March 31, 2024					
Critical Illness Recovery Hospital	Rehabilitation Hospital	Outpatient Rehabilitation	Concentra	Other	Total	Critical Illness Recovery Hospital	Rehabilitation Hospital	Outpatient Rehabilitation	Concentra		
(in thousands)						(in thousands)					

Adjusted EBITDA	Adjusted EBITDA	\$ 11,013	\$ 49,772	\$ 25,715	\$ 90,025	\$ (23,412)	Adjusted EBITDA	\$ 115,940	\$ 61,400	\$ 24,928	\$ 96,142	\$ (18,485)	\$ (2,111)
Depreciation and amortization	Depreciation and amortization	(16,055)	(6,994)	(8,157)	(17,781)	(2,472)	Depreciation and amortization	(17,157)	(7,135)	(7,135)	(9,181)	(9,181)	(18,485)
Stock compensation expense	Stock compensation expense	—	—	—	(535)	(9,652)	Stock compensation expense	—	—	—	—	(166)	(166)
Concentra separation transaction costs <sup>(1)</sup>	Income (loss) from operations	—	—	—	—	—	—	—	—	—	—	—	—
Income (loss) from operations	Income (loss) from operations	—	—	—	—	—	—	—	—	—	—	—	—
Income (loss) from operations	Income (loss) from operations	\$ (5,042)	\$ 42,778	\$ 17,558	\$ 71,709	\$ (35,536)	\$ 91,467	—	—	—	—	—	—
Equity in earnings of unconsolidated subsidiaries	Equity in earnings of unconsolidated subsidiaries	—	—	—	—	—	—	—	—	—	—	—	—
Equity in earnings of unconsolidated subsidiaries	Equity in earnings of unconsolidated subsidiaries	—	—	—	—	—	—	—	—	—	—	—	—
Equity in earnings of unconsolidated subsidiaries	Equity in earnings of unconsolidated subsidiaries	—	—	—	—	—	—	—	—	—	—	—	—
Interest expense	Interest expense	—	—	—	—	—	—	—	—	—	—	—	—
Interest expense	Interest expense	—	—	—	—	—	—	—	—	—	—	—	—
Interest expense	Interest expense	—	—	—	—	—	—	—	—	—	—	—	—
Income before income taxes	Income before income taxes	—	—	—	—	—	\$ 54,347	—	—	—	—	—	—

Three Months Ended September 30, 2023						
	Critical Illness Recovery Hospital	Rehabilitation Hospital	Outpatient Rehabilitation	Concentra	Other	Total
(in thousands)						
Adjusted EBITDA	\$ 46,362	\$ 53,626	\$ 26,346	\$ 98,907	\$ (31,404)	
Depreciation and amortization	(16,402)	(7,106)	(8,861)	(17,959)	(2,066)	
Stock compensation expense	—	—	—	—	(11,483)	
Income (loss) from operations	\$ 29,960	\$ 46,520	\$ 17,485	\$ 80,948	\$ (44,953)	\$ 129,960
Loss on early retirement of debt	—	—	—	—	—	(14,692)
Equity in earnings of unconsolidated subsidiaries	—	—	—	—	—	11,561
Interest expense	—	—	—	—	—	(50,271)
Income before income taxes	—	—	—	—	—	\$ 76,558

Nine Months Ended September 30, 2022						
	Critical Illness Recovery Hospital	Rehabilitation Hospital	Outpatient Rehabilitation	Concentra	Other	Total
(in thousands)						
Adjusted EBITDA	\$ 66,999	\$ 141,996	\$ 85,912	\$ 272,101	\$ (69,054)	
Depreciation and amortization	(45,276)	(20,971)	(24,316)	(55,323)	(7,693)	
Stock compensation expense	—	—	—	(1,606)	(26,350)	
Income (loss) from operations	\$ 21,723	\$ 121,025	\$ 61,596	\$ 215,172	\$ (103,097)	\$ 316,419
Equity in earnings of unconsolidated subsidiaries	—	—	—	—	—	19,648
Interest expense	—	—	—	—	—	(121,770)

Income before income taxes	\$ 214,297						
<b>Nine Months Ended September 30, 2023</b>							
	<b>Critical Illness Recovery</b>	<b>Hospital</b>	<b>Rehabilitation</b>	<b>Outpatient Rehabilitation</b>	<b>Concentra</b>	<b>Other</b>	<b>Total</b>
(in thousands)							
Adjusted EBITDA	\$ 188,631	\$ 155,531	\$ 89,395	\$ 293,046	\$ (99,234)		
Depreciation and amortization	(46,925)	(20,881)	(26,097)	(54,552)	(6,303)		
Stock compensation expense	—	—	—	(178)	(31,812)		
Income (loss) from operations	\$ 141,706	\$ 134,650	\$ 63,298	\$ 238,316	\$ (137,349)	\$ 440,621	
Loss on early retirement of debt							(14,692)
Equity in earnings of unconsolidated subsidiaries							30,618
Interest expense							(147,839)
Income before income taxes							\$ 308,708

(1) Concentra separation transaction costs represent incremental consulting, legal, and audit-related fees incurred in connection with the Company's planned separation of the Concentra segment into a new, publicly traded company and are included within general and administrative expenses on the Condensed Consolidated Statements of Operations.

#### 11.12. Revenue from Contracts with Customers

The following tables disaggregate the Company's revenue for the three and nine months ended September 30, 2022 March 31, 2023 and 2023: 2024:

<b>Three Months Ended September 30, 2022</b>									
<b>Three Months Ended March 31, 2023</b>									
<b>Three Months Ended March 31, 2023</b>									
<b>Three Months Ended September 30, 2023</b>									
	<b>Critical Illness Recovery</b>	<b>Hospital</b>	<b>Rehabilitation</b>	<b>Outpatient Rehabilitation</b>	<b>Concentra</b>	<b>Other</b>	<b>Total</b>		
	(in thousands)								
Patient service revenue:	Patient service revenue:								
Medicare	Medicare	\$ 201,558	\$ 106,584	\$ 45,193	\$ 205	\$ —	\$ 353,540		
Non-Medicare	Non-Medicare	320,896	111,509	221,275	443,040	—	1,096,720		
Total patient services revenues	Total patient services revenues	522,454	218,093	266,468	443,245	—	1,450,260		
Other revenue	Other revenue	2,130	11,294	18,525	1,331	84,254	117,534		
Total revenue	Total revenue	\$ 524,584	\$ 229,387	\$ 284,993	\$ 444,576	\$ 84,254	\$ 1,567,794		
<b>Three Months Ended September 30, 2023</b>									
	<b>Critical Illness Recovery</b>	<b>Hospital</b>	<b>Rehabilitation</b>	<b>Outpatient Rehabilitation</b>	<b>Concentra</b>	<b>Other</b>	<b>Total</b>		
	(in thousands)								

									(in thousands)
<b>Patient service revenue:</b>									
Medicare	\$ 201,881	\$ 115,145	\$ 45,286	\$ 261	\$ —	\$ 362,573			
Non-Medicare	360,847	119,524	228,386	472,171	—	—	1,180,928		
Total patient services revenues	562,728	234,669	273,672	472,432	—	—	1,543,501		
Other revenue	900	12,432	18,132	1,532	89,197	89,197	122,193		
<b>Total revenue</b>	<b>\$ 563,628</b>	<b>\$ 247,101</b>	<b>\$ 291,804</b>	<b>\$ 473,964</b>	<b>\$ 89,197</b>	<b>\$ 89,197</b>	<b>\$ 1,665,694</b>		

									Nine Months Ended September 30, 2022						
Critical Illness Recovery				Outpatient											
Hospital		Rehabilitation Hospital		Rehabilitation		Concentra		Other	Total						
(in thousands)															
<b>Patient service revenue:</b>															
Medicare	\$ 634,225	\$ 314,635	\$ 131,530	\$ 577	\$ —	\$ 1,080,967									
Non-Medicare	1,031,000	331,652	660,345	1,304,865	—	—	3,327,862								
Total patient services revenues	1,665,225	646,287	791,875	1,305,442	—	—	4,408,829								
Other revenue	7,022	32,621	52,316	3,914	247,380	247,380	343,253								
<b>Total revenue</b>	<b>\$ 1,672,247</b>	<b>\$ 678,908</b>	<b>\$ 844,191</b>	<b>\$ 1,309,356</b>	<b>\$ 247,380</b>	<b>\$ 247,380</b>	<b>\$ 4,752,082</b>								

									Nine Months Ended September 30, 2023						
Critical Illness Recovery				Outpatient											
Hospital		Rehabilitation Hospital		Rehabilitation		Concentra		Other	Total						
(in thousands)															
<b>Patient service revenue:</b>															
Medicare	\$ 639,007	\$ 338,650	\$ 137,734	\$ 754	\$ —	\$ 1,116,145									
Non-Medicare	1,090,650	344,885	696,617	1,392,136	—	—	3,524,288								
Total patient services revenues	1,729,657	683,535	834,351	1,392,890	—	—	4,640,433								
Other revenue	2,988	35,884	56,328	4,451	265,118	265,118	364,769								
<b>Total revenue</b>	<b>\$ 1,732,645</b>	<b>\$ 719,419</b>	<b>\$ 890,679</b>	<b>\$ 1,397,341</b>	<b>\$ 265,118</b>	<b>\$ 265,118</b>	<b>\$ 5,005,202</b>								

12.

									Three Months Ended March 31, 2024						
Critical Illness				Outpatient											
Recovery Hospital		Rehabilitation Hospital		Rehabilitation		Concentra		Other	Total						
(in thousands)															
<b>Patient service revenue:</b>															
Medicare	\$ 226,261	\$ 126,386	\$ 45,841	\$ 266	\$ —	\$ 398,754									
Non-Medicare	428,666	126,577	239,613	465,601	—	—	1,260,457								
Total patient services revenues	654,927	252,963	285,454	465,867	—	—	1,659,211								
Other revenue	953	12,737	17,704	1,731	96,473	96,473	129,598								
<b>Total revenue</b>	<b>\$ 655,880</b>	<b>\$ 265,700</b>	<b>\$ 303,158</b>	<b>\$ 467,598</b>	<b>\$ 96,473</b>	<b>\$ 96,473</b>	<b>\$ 1,788,809</b>								

### 13. Earnings per Share

The Company's capital structure includes common stock and unvested restricted stock awards. To compute earnings per share ("EPS"), the Company applies the two-class method because the Company's unvested restricted stock awards are participating securities which are entitled to participate equally with the Company's common stock in undistributed earnings. Application of the Company's two-class method is as follows:

- (i) Net income attributable to the Company is reduced by the amount of dividends declared and by the contractual amount of dividends that must be paid for the current period for each class of stock. There were no contractual dividends paid for the three and nine months ended **September 30, 2022** **March 31, 2023** and **2023, 2024**.

- (ii) The remaining undistributed net income of the Company is then equally allocated to its common stock and unvested restricted stock awards, as if all of the earnings for the period had been distributed. The total net income allocated to each security is determined by adding both distributed and undistributed net income for the period.
- (iii) The net income allocated to each security is then divided by the weighted average number of outstanding shares for the period to determine the EPS for each security considered in the two-class method.

The following table sets forth the net income attributable to the Company, its common shares outstanding, and its participating securities outstanding.

Basic and Diluted EPS						
	Three Months Ended		Nine Months Ended			
	September 30,	2022	September 30,	2022	2023	
(in thousands)						
	Basic and Diluted					
	EPS					
	Basic and Diluted					
	EPS					
	Basic and Diluted					
	EPS					
Three Months Ended March						
	31,					
	2023					
(in thousands)						
Net income	Net income	\$ 38,126	\$60,816	\$160,314	\$237,933	
Less: net income attributable to non-controlling interests	Less: net income attributable to non-controlling interests	10,960	12,636	28,824	40,711	
Net income attributable to the Company	Net income attributable to the Company	27,166	48,180	131,490	197,222	
Less: Distributed and undistributed income attributable to participating securities	Less: Distributed and undistributed income attributable to participating securities	992	1,722	4,588	7,155	
Distributed and undistributed income attributable to common shares	Distributed and undistributed income attributable to common shares	\$ 26,174	\$46,458	\$126,902	\$190,067	

The following tables set forth the computation of EPS under the two-class method:

Three Months Ended September 30,		
	2022	2023

		Basic Allocation		Net Income Allocation		Basic Allocation	
		Net Income Allocation	Shares <sup>(1)</sup> EPS	Net Income Allocation	Shares <sup>(1)</sup> EPS	Net Income Allocation	Shares <sup>(1)</sup> EPS
(in thousands, except for per share amounts)							
Three Months Ended March 31,					Three Months Ended March 31,		
2023		2023		2024			
Net Income Allocation		Net Income Allocation		Net Income Allocation		Net Income Allocation	
(in thousands, except for per share amounts)							
Common shares	Common shares	\$ 26,174	122,193	\$ 0.21	\$ 46,458	123,400	\$ 0.38
Participating securities	Participating securities	992	4,631	\$ 0.21	1,722	4,574	\$ 0.38
Total Company	Total Company	\$ 27,166			\$ 48,180		
Nine Months Ended September 30,							
2022				2023			
Net Income Allocation		Shares <sup>(1)</sup>		Basic and Diluted EPS		Net Income Allocation	
(in thousands, except for per share amounts)							
Common shares		\$ 126,902	125,341	\$ 1.01	\$ 190,067	122,865	\$ 1.55
Participating securities		4,588	4,532	\$ 1.01	7,155	4,625	\$ 1.55
Total Company		\$ 131,490			\$ 197,222		

(1) Represents the weighted average share count outstanding during the period.

## 13.14. Commitments and Contingencies

### Litigation

The Company is a party to various legal actions, proceedings, and claims (some of which are not insured), and regulatory and other governmental audits and investigations in the ordinary course of its business. The Company cannot predict the ultimate outcome of pending litigation, proceedings, and regulatory and other governmental audits and investigations. These matters could potentially subject the Company to sanctions, damages, recoupments, fines, and other penalties. The Department of Justice, Centers for Medicare & Medicaid Services ("CMS"), or other federal and state enforcement and regulatory agencies may conduct additional investigations related to the Company's businesses in the future that may, either individually or in the aggregate, have a material adverse effect on the Company's business, financial position, results of operations, and liquidity.

To address claims arising out of the Company's operations, the Company maintains professional malpractice liability insurance and general liability insurance coverages through a number of different programs that are dependent upon such factors as the state where the Company is operating and whether the operations are wholly owned or are operated through a joint venture. For the Company's wholly owned hospital and outpatient clinic operations, the Company currently maintains insurance coverages under a combination of policies with a total annual aggregate limit of up to \$37.0 million for professional malpractice liability insurance and \$40.0 million for general liability insurance. For the Company's Concentra center operations, the Company currently maintains insurance coverages under a combination of policies with a total annual aggregate limit of up to **\$19.0 million** \$29.0 million for professional malpractice liability insurance and **\$19.0 million** \$29.0 million for general liability insurance. The Company's insurance for the professional liability coverage is written on a "claims-made" basis, and its commercial general liability coverage is maintained on an "occurrence" basis. These coverages apply after a self-insured retention limit is exceeded. For the Company's joint venture operations, the Company has designed a separate insurance program that responds to the risks of specific joint ventures. Most of the Company's joint ventures are insured under a master program with an annual aggregate limit of up to \$80.0 million, subject to a sublimit aggregate ranging from \$23.0 million to \$33.0 million. The policies are generally written on a "claims-made" basis. Each of these programs has either a deductible or self-insured retention limit. The Company also maintains additional types of liability insurance covering claims that which, due to their nature or amount, are not covered by or not fully covered by the Company's applicable professional malpractice and general liability insurance policies. These policies, including workers compensation, property and casualty, directors and officers, cyber liability insurance, and employment practices liability insurance coverages. Our insurance policies also do not generally cover are silent with respect to punitive damages so coverage is available to the extent insurable under the law of any applicable jurisdiction, and are subject to various deductibles and policy limits. The Company reviews its insurance program annually and may make adjustments to the amount of insurance coverage and self-insured retentions in future years. Significant legal actions, as well as the cost and possible lack of available insurance, could subject the Company to substantial uninsured liabilities. In the Company's opinion, the outcome of these actions, individually or in the aggregate, will not have a material adverse effect on its financial position, results of operations, or cash flows.

Healthcare providers are subject to lawsuits under the qui tam provisions of the federal False Claims Act. Qui tam lawsuits typically remain under seal (hence, usually unknown to the defendant) for some time while the government decides whether or not to intervene on behalf of a private qui tam plaintiff (known as a relator) and take the lead in the litigation. These lawsuits can involve significant monetary damages and penalties and award bounties to private plaintiffs who successfully bring the suits. The Company is and has been a defendant in these cases in the past, and may be named as a defendant in similar cases from time to time in the future.

**Oklahoma City Subpoena Investigation.** On August 24, 2020, the Company and Select Specialty Hospital – Oklahoma City, Inc. ("SSH-Oklahoma City") received **Civil Investigative Demands** ("CIDs") from the U.S. Attorney's Office for the Western District of Oklahoma seeking responses to interrogatories and the production of various documents principally relating to the documentation, billing and reviews of medical services furnished to patients at SSH-Oklahoma City. The Company understands that the investigation arose from a qui tam lawsuit alleging billing fraud related to charges for respiratory therapy services at **SSH-Oklahoma** **SSH-Oklahoma** City and Select Specialty Hospital **H** Wichita, Inc. The Company has produced documents in response to the CIDs and is fully cooperating with this investigation. At this time, the Company is unable to predict the timing and outcome of this matter.

**Physical Therapy Billing.** On October 7, 2021, the Company received a letter from a Trial Attorney at the U.S. Department of Justice, Civil Division, Commercial Litigation Branch, Fraud Section ("DOJ") stating that the DOJ, in conjunction with the U.S. Department of Health and Human Services ("HHS"), is investigating the Company in connection with potential violations of the False Claims Act, 31 U.S.C. § 3729, *et seq.* The letter specified that the investigation relates to the Company's billing for physical therapy services, and indicated that the DOJ would be requesting certain records from the Company. In **October and December 2021**, the DOJ requested, and the Company furnished, records relating to six of the Company's outpatient therapy clinics in Florida. In **2022 and 2023**, the DOJ requested certain data relating to all of the Company's outpatient therapy clinics nationwide, and sought information about the Company's ability to produce additional data relating to the physical therapy services furnished by the Company's outpatient therapy clinics and Concentra. The Company has produced data and other documents requested by the DOJ and is fully cooperating on this investigation. At this time, the Company is unable to predict the timing and outcome of this matter.

**California Department of Insurance Investigation.** On February 5, 2024, Concentra received a subpoena from the California Department of Insurance relating to an investigation under the California Insurance Frauds Prevention Act ("IFPA"), Cal. Ins. Code § 1871.7 *et seq.*, which allows a whistleblower to file a false claims lawsuit based on the submission of false or fraudulent claims to insurance companies. The subpoena seeks documentation relating mainly to Concentra's billing and coding for physical therapy claims submitted to commercial insurers and workers compensation carriers located or doing business in California. The Company has produced data and other documents requested by the California Department of Insurance and is fully cooperating on this investigation. At this time, the Company is unable to predict the timing and outcome of this matter.

**14. Perry Johnson & Associates, Inc. Data Breach.** On November 10, 2023, Perry Johnson & Associates, Inc., a third-party vendor of health information technology solutions that provides medical transcription services ("PJ&A"), notified Concentra Health Services, Inc. ("Concentra") that certain information related to particular Concentra patients was potentially affected by a cybersecurity event. In February 2024, Concentra sent notices to almost four million patients who may have been impacted by the data breach. During the first quarter of 2024, Concentra became aware of six putative class action lawsuits filed against PJ&A and Concentra related to the data breach. The first was filed in the U.S. District Court for the Eastern District of Michigan on February 19, 2024 by Elliot Curry, individually and on behalf of all others similarly situated. Plaintiff alleged, among other things, that he became the victim of identity theft as a result of the PJ&A data breach and that Concentra had lax data security policies. The second was filed in the U.S. District Court for the Eastern District of New York on February 21, 2024 by Tiffany Williams and Jo Joaquin, individually and on behalf of all others similarly situated. Plaintiffs alleged, among other things, that they face an immediate and heightened risk of identity theft as a result of the data breach and that the defendants failed to take measures to properly safeguard their private information. The third was filed in the U.S. District Court for the Eastern District of Missouri on February 26, 2024 by Stephen Tate, a.k.a. Steven Tate, individually and on behalf of all others similarly situated. Plaintiff alleged, among other things, that he faces a heightened and imminent risk of identity theft as a result of the data breach and that the defendants failed to take measures to properly safeguard his private information. The fourth was filed in the U.S. District Court for the Eastern District of Michigan on February 26, 2024 by Eric Franczak, individually and on behalf of all others similarly situated. Plaintiff alleged, among other things, that he faces a substantially increased risk of fraud and identity theft as a result of the data breach and that the defendants failed to take measures to properly safeguard his private information. The fifth was filed in the U.S. District Court for the Eastern District of Michigan on March 6, 2024 by Lazema Johnson, individually and on behalf of all others similarly situated. Plaintiff alleged, among other things, that she faces a substantially increased risk of fraud and identity theft as a result of the data breach and that the defendants failed to take measures to properly safeguard her private information. The sixth was filed in the Superior Court of California, County of Los Angeles, on April 8, 2024 by Robert Valencia, individually and on behalf of all others similarly situated. Plaintiff alleged, among other things, that he faces a substantially increased risk of fraud and identity theft as a result of the data breach and that the defendants failed to take measures to properly safeguard his private information. The Company is working with its cybersecurity risk insurance policy carrier and does not believe that the data breach or the lawsuits will have a material impact on its operations or financial performance. However, at this time, the Company is unable to predict the timing and outcome of these matters.

## **15. Subsequent Events**

On **November 2, 2023** **May 1, 2024**, the Company's Board of Directors declared a cash dividend of \$0.125 per share. The dividend will be payable on or about **November 28, 2023** **May 30, 2024**, to stockholders of record as of the close of business on **November 15, 2023** **May 16, 2024**.

## **ITEM 2. MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS**

*You should read this discussion together with our unaudited condensed consolidated financial statements and accompanying notes.*

### **Forward-Looking Statements**

This report on Form 10-Q contains forward-looking statements within the meaning of the federal securities laws. Statements that are not historical facts, including statements about our beliefs and expectations, are forward-looking statements. Forward-looking statements include statements preceded by, followed by or that include the words "may," "could," "would," "should," "believe," "expect," "anticipate," "plan," "target," "estimate," "project," "intend," and similar expressions. These statements include, among others, statements regarding our expected business outlook, anticipated financial and operating results, including the potential impact of the COVID-19 pandemic on those financial and operating results, our business strategy and means to implement our strategy, our objectives, the amount and timing of capital expenditures, the likelihood of our success in expanding our business, financing plans, budgets, working capital needs, and sources of liquidity.

Forward-looking statements are only predictions and are not guarantees of performance. These statements are based on our management's beliefs and assumptions, which in turn are based on currently available information. Important assumptions relating to the forward-looking statements include, among others, assumptions regarding our services, the expansion of our services, competitive conditions, and general economic conditions. These assumptions could prove inaccurate. Forward-looking statements also involve known and unknown risks and uncertainties, which could cause actual results to differ materially from those contained in any forward-looking statement. Many of these factors are beyond our ability to control or predict. Such factors include, but are not limited to, the following:

- changes in government reimbursement for our services and/or new payment policies may result in a reduction in revenue, an increase in costs, and a reduction in profitability;
- adverse economic conditions including an inflationary environment could cause us to continue to experience increases in the prices of labor and other costs of doing business resulting in a negative impact on our business, operating results, cash flows, and financial condition;
- shortages in qualified nurses, therapists, physicians, or other licensed providers, and/or the inability to attract or retain qualified healthcare professionals could limit our ability to staff our facilities;
- shortages in qualified health professionals could cause us to increase our dependence on contract labor, increase our efforts to recruit and train new employees, and expand upon our initiatives to retain existing staff, which could increase our operating costs significantly;
- the continuing effects public threats such as a global pandemic, or widespread outbreak of an infectious disease, similar to the COVID-19 pandemic, including, but not limited to, the prolonged disruption to the could negatively impact patient volumes and revenues, increase labor and other operating costs, disrupt global financial markets, increased operational costs due to recessionary pressures and labor costs, additional measures taken by government authorities and the private sector to limit the spread of COVID-19, and and/or further legislative and regulatory actions which impact healthcare providers, including actions that may impact the Medicare program;
- changes in government reimbursement for our services and/or new payment policies may result in a reduction in revenue, an increase in costs, and a reduction in profitability;
- the failure of our Medicare-certified long term care hospitals or inpatient rehabilitation facilities to maintain their Medicare certifications may cause our revenue and profitability to decline;
- the failure of our Medicare-certified long term care hospitals and inpatient rehabilitation facilities operated as "hospitals within hospitals" to qualify as hospitals separate from their host hospitals may cause our revenue and profitability to decline;
- a government investigation or assertion that we have violated applicable regulations may result in sanctions or reputational harm and increased costs;
- acquisitions or joint ventures may prove difficult or unsuccessful, use significant resources, or expose us to unforeseen liabilities;
- our plans and expectations related to our acquisitions and our ability to realize anticipated synergies;
- failure to complete or achieve some or all the expected benefits of the potential separation of Concentra;
- private third-party payors for our services may adopt payment policies that could limit our future revenue and profitability;

  

- the failure to maintain established relationships with the physicians in the areas we serve could reduce our revenue and profitability;

  

- competition may limit our ability to grow and result in a decrease in our revenue and profitability;
- the loss of key members of our management team could significantly disrupt our operations;
- the effect of claims asserted against us could subject us to substantial uninsured liabilities;
- a security breach of our or our third-party vendors' information technology systems may subject us to potential legal and reputational harm and may result in a violation of the Health Insurance Portability and Accountability Act of 1996 or the Health Information Technology for Economic and Clinical Health Act; and
- other factors discussed from time to time in our filings with the SEC, including factors discussed under the heading "Risk Factors" in our quarterly reports on Form 10-Q and in our Annual Report on Form 10-K for the year ended December 31, 2022 December 31, 2023.

Except as required by applicable law, including the securities laws of the United States and the rules and regulations of the SEC, we are under no obligation to publicly update or revise any forward-looking statements, whether as a result of any new information, future events, or otherwise. You should not place undue reliance on our forward-looking statements. Although we believe that the expectations reflected in forward-looking statements are reasonable, we cannot guarantee future results or performance.

Investors should also be aware that while we do, from time to time, communicate with securities analysts, it is against our policy to disclose to securities analysts any material non-public information or other confidential commercial information. Accordingly, stockholders should not assume that we agree with any statement or report issued by any securities analyst irrespective of the content of the statement or report. Thus, to the extent that reports issued by securities analysts contain any projections, forecasts or opinions, such reports are not the responsibility of the Company.

## Overview

We began operations in 1997 and, based on number of facilities, are one of the largest operators of critical illness recovery hospitals, rehabilitation hospitals, outpatient rehabilitation clinics, and occupational health centers in the United States. As of **September 30, 2023** **March 31, 2024**, we had operations in 46 states and the District of Columbia. We operated 107 critical illness recovery hospitals in 28 states, 33 rehabilitation hospitals in 13 states, **1,946** **1,922** outpatient rehabilitation clinics in 39 states and the District of Columbia, **539** **547** occupational health centers in 41 states, and **145** **151** onsite clinics at employer worksites.

Our reportable segments include the critical illness recovery hospital segment, the rehabilitation hospital segment, the outpatient rehabilitation segment, and the Concentra segment. We had revenue of **\$5,005.2 million** **\$1,788.8 million** for the **nine** **three** months ended **September 30, 2023** **March 31, 2024**. Of this total, we earned approximately **35%** **37%** of our revenue from our critical illness recovery hospital segment, approximately **14%** **15%** from our rehabilitation hospital segment, approximately **18%** **17%** from our outpatient rehabilitation segment, and approximately **28%** **26%** from our Concentra segment. Our critical illness recovery hospital segment consists of hospitals designed to serve the needs of patients recovering from critical illnesses, often with complex medical needs, and our rehabilitation hospital segment consists of hospitals designed to serve patients that require intensive physical rehabilitation care. Patients are typically admitted to our critical illness recovery hospitals and rehabilitation hospitals from general acute care hospitals. Our outpatient rehabilitation segment consists of clinics that provide physical, occupational, and speech rehabilitation services. Our Concentra segment consists of occupational health centers that provide workers' compensation injury care, physical therapy, and consumer health services as well as onsite clinics located at employer worksites that deliver occupational **medicine** **health** services.

On January 3, 2024, the Company announced its intention to separate Concentra, with the intention to create a new, publicly traded company by the end of the fiscal year 2024. On February 27, 2024, we received a private letter ruling from the U.S. Internal Revenue Service to the effect that the distribution of Concentra's common stock to Select and our stockholders will be tax-free for U.S federal income tax purposes. On March 18, 2024, Concentra confidentially submitted a draft registration statement on Form S-1 with the SEC relating to the proposed initial public offering of its common stock. The number of shares to be offered and the price range for the proposed offering have not yet been determined. The initial public offering is expected to occur after the SEC completes its review process, subject to market and other conditions. There can be no assurance regarding the ultimate timing of the planned separation or that such separation will be completed.

## Impact of the Change Healthcare Cybersecurity Incident

On February 22, 2024, UnitedHealth Group Incorporated indicated in a Form 8-K filing, that a cyber security threat actor had gained access to some of its Change Healthcare information technology systems. Upon receiving notification of the incident, we severed connectivity with all Change Healthcare-related systems and we are not aware of any impact on our own information technology systems. However, as a result of the incident, certain of our patient billing and collections processes were disrupted and alternative platforms needed to be enabled to resume normal patient billing and collections operations. The Company began to reconnect to certain applications maintained by Change Healthcare in late March 2024.

As of March 31, 2024, the impact on the Company was primarily a decrease in cash flows from operations, as further described in *Liquidity and Capital Resources*, driven by an increase in accounts receivable that is expected to return to more normalized levels in the second and third quarters of 2024. Although we utilized borrowing capacity under our revolving facility to fund the temporary shortfall in cash flows from operations, the Company continues to maintain strong liquidity and to date, the Change Healthcare incident has not had a material impact on the Company's results of operations or financial condition.

## Non-GAAP Measure

We believe that the presentation of Adjusted EBITDA, as defined below, is important to investors because Adjusted EBITDA is commonly used as an analytical indicator of performance by investors within the healthcare industry. Adjusted EBITDA is used by management to evaluate financial performance and determine resource allocation for each of our segments. Adjusted EBITDA is not a measure of financial performance under GAAP. Items excluded from Adjusted EBITDA are significant components in understanding and assessing financial performance. Adjusted EBITDA should not be considered in isolation or as an alternative to, or substitute for, net income, income from operations, cash flows generated by operations, investing or financing activities, or other financial statement data presented in the consolidated financial statements as indicators of financial performance or liquidity. Because Adjusted EBITDA is not a measurement determined in accordance with GAAP and is thus susceptible to varying definitions, Adjusted EBITDA as presented may not be comparable to other similarly titled measures of other companies.

We define Adjusted EBITDA as earnings excluding interest, income taxes, depreciation and amortization, gain (loss) on early retirement of debt, stock compensation expense, transaction costs associated with the Concentra separation, gain (loss) on sale of businesses, and equity in earnings (losses) of unconsolidated subsidiaries. We will refer to Adjusted EBITDA throughout the remainder of Management's Discussion and Analysis of Financial Condition and Results of Operations.

The following table reconciles net income and income from operations to Adjusted EBITDA and should be referenced when we discuss Adjusted EBITDA:

		Three Months Ended September 30,		Nine Months Ended September 30,		Three Months Ended March 31,	
		2022	2023	2022	2023	2023	2024
		(in thousands)					
Net income	Net income	\$ 38,126	\$ 60,816	\$ 160,314	\$ 237,933		
Income tax expense	Income tax expense	16,221	15,742	53,983	70,775		
Interest expense	Interest expense	45,204	50,271	121,770	147,839		
Equity in earnings of unconsolidated subsidiaries	Equity in earnings of unconsolidated subsidiaries	(8,084)	(11,561)	(19,648)	(30,618)		
Loss on early retirement of debt		—	14,692	—	14,692		
Equity in earnings of unconsolidated subsidiaries							
Equity in earnings of unconsolidated subsidiaries							
Income from operations							
Income from operations							
Income from operations	Income from operations	91,467	129,960	316,419	440,621		
Stock compensation expense:	Stock compensation expense:						
Included in general and administrative	Included in general and administrative	8,000	9,425	21,995	26,383		
Included in cost of services	Included in cost of services	2,187	2,058	5,961	5,607		
Depreciation and amortization	Depreciation and amortization	51,459	52,394	153,579	154,758		
Concentra separation transaction costs <sup>(1)</sup>							
Adjusted EBITDA	Adjusted EBITDA	\$153,113	\$193,837	\$497,954	\$627,369		

(1) Concentra separation transaction costs represent incremental consulting, legal, and audit-related fees incurred in connection with the Company's planned separation of the Concentra segment into a new, publicly traded company and are included within general and administrative expenses on the Condensed Consolidated Statements of Operations.

## Summary Financial Results

### Three Months Ended September 30, 2023 March 31, 2024

The following tables reconcile our segment performance measures to our consolidated operating results:

Three Months Ended September 30, 2023	Three Months Ended March 31, 2024
---------------------------------------	-----------------------------------

		Critical Illness Recovery Hospital						Rehabilitation Hospital					
		Critical Illness Recovery Hospital	Rehabilitation Hospital	Outpatient Rehabilitation	Concentra	Other	Total	Critical Illness Recovery Hospital	Rehabilitation Hospital	Outpatient Rehabilitation	Concentra	Other	Total
		(in thousands)						(in thousands)					
(in thousands)													
Revenue	Revenue	\$ 563,628	\$ 247,101	\$ 291,804	\$ 473,964	\$ 89,197	\$ 1,665,694						
Operating expenses	Operating expenses	(517,266)	(193,475)	(265,458)	(375,057)	(132,569)	(1,483,825)						
Depreciation and amortization	Depreciation and amortization	(16,402)	(7,106)	(8,861)	(17,959)	(2,066)	(52,394)						
Other operating income	Other operating income	—	—	—	—	485	485						
Income (loss) from operations	Income (loss) from operations	\$ 29,960	\$ 46,520	\$ 17,485	\$ 80,948	\$ (44,953)	\$ 129,960						
Depreciation and amortization	Depreciation and amortization	16,402	7,106	8,861	17,959	2,066	52,394						
Concentra separation transaction costs	Concentra separation transaction costs												
Stock compensation expense	Stock compensation expense	—	—	—	—	11,483	11,483						
Adjusted EBITDA	Adjusted EBITDA	\$ 46,362	\$ 53,626	\$ 26,346	\$ 98,907	\$ (31,404)	\$ 193,837						
Adjusted EBITDA margin	Adjusted EBITDA margin	8.2 %	21.7 %	9.0 %	20.9 %	N/M	11.6 %	Adjusted EBITDA margin	17.7 %	23.1 %	8.2 %	20.6 %	N/M 14.6 %
		Three Months Ended September 30, 2022						Three Months Ended March 31, 2023					
		Critical Illness Recovery Hospital	Rehabilitation Hospital	Outpatient Rehabilitation	Concentra	Other	Total	Critical Illness Recovery Hospital	Rehabilitation Hospital	Outpatient Rehabilitation	Concentra	Other	Total
		(in thousands)						(in thousands)					
Revenue	Revenue	\$ 524,584	\$ 229,387	\$ 284,993	\$ 444,576	\$ 84,254	\$ 1,567,794						
Operating expenses	Operating expenses	(513,691)	(179,856)	(259,278)	(355,086)	(125,397)	(1,433,308)						
Depreciation and amortization	Depreciation and amortization	(16,055)	(6,994)	(8,157)	(17,781)	(2,472)	(51,459)						
Other operating income	Other operating income	120	241	—	—	8,079	8,440						
Income (loss) from operations	Income (loss) from operations												
Income (loss) from operations	Income (loss) from operations												
Income (loss) from operations	Income (loss) from operations	\$ (5,042)	\$ 42,778	\$ 17,558	\$ 71,709	\$ (35,536)	\$ 91,467						

Depreciation and amortization	Depreciation and amortization	16,055	6,994	8,157	17,781	2,472	51,459
Stock compensation expense	Stock compensation expense	—	—	—	535	9,652	10,187
Adjusted EBITDA	Adjusted EBITDA	\$ 11,013	\$ 49,772	\$ 25,715	\$ 90,025	\$ (23,412)	\$ 153,113
Adjusted EBITDA margin	Adjusted EBITDA margin	2.1 %	21.7 %	9.0 %	20.2 %	N/M	9.8 %
							Adjusted EBITDA margin 12.9 %
							20.4 %
							10.2 %
							20.5 %
							N/M 12.9 %

Net income was \$60.8 million \$117.2 million for the three months ended September 30, 2023 March 31, 2024, compared to \$38.1 million \$85.3 million for the three months ended September 30, 2022 March 31, 2023.

The following table summarizes the changes in our segment performance measures for the three months ended September 30, 2023 March 31, 2024, compared to the three months ended September 30, 2022 March 31, 2023:

	Critical Illness Recovery Hospital						Rehabilitation Hospital						Outpatient Rehabilitation					
	Illness Recovery	Rehabilitation Hospital	Outpatient Rehabilitation	Concentra	Other	Total	Critical Illness Recovery	Hospital	Rehabilitation Hospital	Outpatient Rehabilitation	Concentra	Other	Total					
Change in revenue	Change in revenue	7.4 %	7.7 %	2.4 %	6.6 %	5.9 %	6.2 %	Change in revenue	10.4 %	14.8 %	2.5 %	2.5 %	10.4 %	7.4 %				
Change in income from operations	Change in income from operations	694.2 %	8.7 %	(0.4) %	12.9 %	N/M	42.1 %	Change in income from operations	64.3 %	34.6 %	(27.6) %	0.3 %	N/M	28.1 %				
Change in Adjusted EBITDA	Change in Adjusted EBITDA	321.0 %	7.7 %	2.5 %	9.9 %	N/M	26.6 %	Change in Adjusted EBITDA	51.0 %	30.0 %	(17.5) %	2.6 %	N/M	22.4 %				

N/M — Not meaningful.

#### Nine Months Ended September 30, 2023

The following tables reconcile our segment performance measures to our consolidated operating results:

	Nine Months Ended September 30, 2023							
	Critical Illness Recovery Hospital		Rehabilitation Hospital		Outpatient Rehabilitation		Concentra	
	(in thousands)							
Revenue	\$ 1,732,645	\$ 719,419	\$ 890,679	\$ 1,397,341	\$ 265,118	\$ 5,005,202		
Operating expenses	(1,544,014)	(564,224)	(801,523)	(1,104,624)	(396,649)	(4,411,034)		
Depreciation and amortization	(46,925)	(20,881)	(26,097)	(54,552)	(6,303)	(154,758)		
Other operating income	—	336	239	151	485	1,211		
Income (loss) from operations	\$ 141,706	\$ 134,650	\$ 63,298	\$ 238,316	\$ (137,349)	\$ 440,621		
Depreciation and amortization	46,925	20,881	26,097	54,552	6,303	154,758		
Stock compensation expense	—	—	—	178	31,812	31,990		
Adjusted EBITDA	\$ 188,631	\$ 155,531	\$ 89,395	\$ 293,046	\$ (99,234)	\$ 627,369		
Adjusted EBITDA margin	10.9 %	21.6 %	10.0 %	21.0 %	N/M	12.5 %		

  

	Nine Months Ended September 30, 2022							
	Critical Illness Recovery Hospital		Rehabilitation Hospital		Outpatient Rehabilitation		Concentra	
	(in thousands)							

Revenue	\$ 1,672,247	\$ 678,908	\$ 844,191	\$ 1,309,356	\$ 247,380	\$ 4,752,082
Operating expenses	(1,605,368)	(537,153)	(758,279)	(1,038,842)	(366,007)	(4,305,649)
Depreciation and amortization	(45,276)	(20,971)	(24,316)	(55,323)	(7,693)	(153,579)
Other operating income (expense)	120	241	—	(19)	23,223	23,565
Income (loss) from operations	\$ 21,723	\$ 121,025	\$ 61,596	\$ 215,172	\$ (103,097)	\$ 316,419
Depreciation and amortization	45,276	20,971	24,316	55,323	7,693	153,579
Stock compensation expense	—	—	—	1,606	26,350	27,956
Adjusted EBITDA	\$ 66,999	\$ 141,996	\$ 85,912	\$ 272,101	\$ (69,054)	\$ 497,954
Adjusted EBITDA margin	4.0 %	20.9 %	10.2 %	20.8 %	N/M	10.5 %

Net income was \$237.9 million for the nine months ended September 30, 2023, compared to \$160.3 million for the nine months ended September 30, 2022.

The following table summarizes the changes in our segment performance measures for the nine months ended September 30, 2023, compared to the nine months ended September 30, 2022:

	Critical Illness Recovery Hospital	Rehabilitation Hospital	Outpatient Rehabilitation	Concentra	Other	Total
Change in revenue	3.6 %	6.0 %	5.5 %	6.7 %	7.2 %	5.3 %
Change in income from operations	552.3 %	11.3 %	2.8 %	10.8 %	N/M	39.3 %
Change in Adjusted EBITDA	181.5 %	9.5 %	4.1 %	7.7 %	N/M	26.0 %

N/M — Not meaningful.

## Regulatory Changes

Our Annual Report on Form 10-K for the year ended December 31, 2022 December 31, 2023, filed with the SEC on February 23, 2023 February 22, 2024, contains a detailed discussion of the regulations that affect our business in Part I — Business — Government Regulations. The following is a discussion of some of the more significant healthcare regulatory changes that have affected our financial performance in the periods covered by this report, or are likely to affect our financial performance and financial condition in the future. The information below should be read in conjunction with the more detailed discussion of regulations contained in our Form 10-K.

### Medicare Reimbursement

The Medicare program reimburses healthcare providers for services furnished to Medicare beneficiaries, which are generally persons age 65 and older, those who are chronically disabled, and those suffering from end stage renal disease. The program is governed by the Social Security Act of 1965 and is administered primarily by the Department of Health and Human Services ("HHS") and CMS. Revenue generated directly from the Medicare program represented approximately 22% and 23% of our revenue for the nine three months ended September 30, 2023 March 31, 2024, and 23% for the year ended December 31, 2022 December 31, 2023, respectively.

### Federal Health Care Program Changes in Response to the COVID-19 Pandemic

On January 31, 2020, HHS declared a public health emergency under section 319 of the Public Health Service Act, 42 U.S.C. § 247d, in response to the COVID-19 outbreak in the United States. The HHS Secretary renewed the public health emergency determination for subsequent 90-day periods until February 9, 2023. On February 9, 2023 through May 11, 2023, the HHS Secretary signed the final renewal and end of the public health emergency ended on May 11, 2023 emergency. The COVID-19 national emergency that was declared by President Trump on March 13, 2020, which was separate from the public health emergency, ended on April 10, 2023 when H.R.J. Res. 7 was signed into law.

As a result of the COVID-19 national emergency, the HHS Secretary authorized the waiver or modification of certain requirements under Medicare, Medicaid, and the Children's Health Insurance Program ("CHIP") pursuant to section 1135 of the Social Security Act. Under this authority, CMS issued a number of blanket waivers that excused health care providers or suppliers from specific program requirements. Our Annual Report on Form 10-K for the year ended December 31, 2022 December 31, 2023, contains a detailed discussion of the federal health care program changes made in response to the COVID-19 pandemic, including these COVID-19 waivers, in Part II — Management's Discussion and Analysis of Financial Condition and Results of Operations — Regulatory Changes. Most of these COVID-19 waivers, including the waiver of the IRF 60% Rule and the waiver of Medicare statutory requirements regarding site neutral payments to long-term care hospitals ("LTCHs"), ended when the public health emergency expired on May 11, 2023. However, LTCHs are exempt from the greater-than-25-day average length of stay requirement for all cost reporting periods that include the COVID-19 public health emergency period. As a result, LTCH cost reporting periods that started prior to May 11, 2023, will continue to be exempt for the remainder of that cost reporting year. However, LTCH cost reporting periods that begin on or after May 11, 2023, must comply with the greater-than-25-day average length of stay requirement.

In addition, the Coronavirus Aid, Relief, and Economic Security ("CARES") Act and related legislation temporarily suspended the 2% cut to Medicare payments due to sequestration from May 1, 2020, through March 31, 2022, and reduced the sequestration adjustment from 2% to 1% from April 1 through June 30, 2022. The full 2% reduction resumed on July 1, 2022. To pay for this relief, Congress increased the sequestration cut to Medicare payments to 2.25% for the first six months of fiscal year 2030 and to 3% for the final six months of fiscal year 2030. Additionally, an across-the-board 4% payment cut required to take effect in January 2022 due to the American Rescue Plan from the FY 2022 Statutory Pay-As-You-Go ("PAYGO") scorecard was deferred by Congress until 2025.

The CARES Act and related legislation also provided more than \$178 billion in appropriations for the Public Health and Social Services Emergency Fund, also known as the Provider Relief Fund, to be used for preventing, preparing, and responding to COVID-19 and for reimbursing "eligible health care providers for health care related expenses or lost revenues that are attributable to coronavirus." HHS began distributing these funds to providers in April 2020. Recipients of payments were required to report data to HHS on the use

of the funds via an online portal by specific deadlines established by HHS based on the date of the payment. All recipients of funds are subject to audit by HHS, the HHS OIG, or the Pandemic Response Accountability Committee. Audits may include examination of the accuracy of the data providers submitted to HHS in their applications for payments. Additional distributions are not expected and as a result, the Company does not expect to recognize additional income associated with these funds in the future.

#### **Medicare Reimbursement of LTCH Services**

The following is a summary of significant regulatory changes to the Medicare prospective payment system for our critical illness recovery hospitals, which are certified by Medicare as LTCHs, which have affected our results of operations, as well as the policies and payment rates that may affect our future results of operations. Medicare payments to our critical illness recovery hospitals are made in accordance with the long-term care hospital prospective payment system ("LTCH-PPS").

**Fiscal Year 2022.** On August 13, 2021, CMS published the final rule updating policies and payment rates for the LTCH-PPS for fiscal year 2022 (affecting discharges and cost reporting periods beginning on or after October 1, 2021, through September 30, 2022). The standard federal rate was set at \$44,714, an increase from the standard federal rate applicable during fiscal year 2021 of \$43,755. The update to the standard federal rate for fiscal year 2022 included a market basket increase of 2.6%, less a productivity adjustment of 0.7%. The standard federal rate also included an area wage budget neutrality factor of 1.002848. The fixed-loss amount for high cost outlier cases paid under LTCH-PPS was set at \$33,015, an increase from the fixed-loss amount in the 2021 fiscal year of \$27,195. The fixed-loss amount for high cost outlier cases paid under the site-neutral payment rate was set at \$30,988, an increase from the fixed-loss amount in the 2021 fiscal year of \$29,064.

**Fiscal Year 2023.** On August 10, 2022, CMS published the final rule updating policies and payment rates for the LTCH-PPS for fiscal year 2023 (affecting discharges and cost reporting periods beginning on or after October 1, 2022, through September 30, 2023). Certain errors in the final rule were corrected in documents published November 4, 2022, and December 13, 2022. The standard federal rate for fiscal year 2023 was set at \$46,433, an increase from the standard federal rate applicable during fiscal year 2022 of \$44,714. The update to the standard federal rate for fiscal year 2023 included a market basket increase of 4.1%, less a productivity adjustment of 0.3%. The standard federal rate also included an area wage budget neutrality factor of 1.0004304. As a result of the CARES Act, all LTCH cases were paid at the standard federal rate during the public health emergency. When the public health emergency ended on May 11, 2023, CMS returned to using the site-neutral payment rate for reimbursement of cases that do not meet the LTCH patient criteria. The fixed-loss amount for high cost outlier cases paid under LTCH-PPS was set at \$38,518, an increase from the fixed-loss amount in the 2022 fiscal year of \$33,015. The fixed-loss amount for high cost outlier cases paid under the site-neutral payment rate was set at \$38,788, an increase from the fixed-loss amount in the 2022 fiscal year of \$30,988.

**Fiscal Year 2024.** On August 28, 2023, CMS published the final rule updating policies and payment rates for the LTCH-PPS for fiscal year 2024 (affecting discharges and cost reporting periods beginning on or after October 1, 2023, through September 30, 2024). Certain errors in the final rule were corrected in a document published on October 4, 2023. The standard federal rate for fiscal year 2024 is \$48,117, an increase from the standard federal rate applicable during fiscal year 2023 of \$46,433. The update to the standard federal rate for fiscal year 2024 includes a market basket increase of 3.5%, less a productivity adjustment of 0.2%. The standard federal rate also includes an area wage budget neutrality factor of 1.0031599. The fixed-loss amount for high cost outlier cases paid under LTCH-PPS is \$59,873, an increase from the fixed-loss amount in the 2023 fiscal year of \$38,518. The fixed-loss amount for high cost outlier cases paid under the site-neutral payment rate is \$42,750, an increase from the fixed-loss amount in the 2023 fiscal year of \$38,788.

**Fiscal Year 2025.** On April 10, 2024, CMS released a display copy of the proposed rule to update policies and payment rates for the LTCH-PPS for fiscal year 2025 (affecting discharges and cost reporting periods beginning on or after October 1, 2024, through September 30, 2025). CMS is expected to issue the final rule in August or shortly thereafter. The proposed standard federal rate for fiscal year 2025 is \$49,263, an increase from the standard federal rate applicable during fiscal year 2024 of \$48,117. The proposed update to the standard federal rate for fiscal year 2025 includes a market basket increase of 3.2%, less a productivity adjustment of 0.4%. The proposed standard federal rate also includes an area wage budget neutrality factor of 0.9959347. The proposed fixed-loss amount for high cost outlier cases paid under LTCH-PPS is \$90,921, an increase from the fixed-loss amount in the 2024 fiscal year of \$59,873. The proposed fixed-loss amount for high cost outlier cases paid under the site-neutral payment rate is \$49,237, an increase from the fixed-loss amount in the 2024 fiscal year of \$42,750.

#### **Medicare Reimbursement of IRF Services**

The following is a summary of significant regulatory changes to the Medicare prospective payment system for our rehabilitation hospitals, which are certified by Medicare as IRFs, which have affected our results of operations, as well as the policies and payment rates that may affect our future results of operations. Medicare payments to our rehabilitation hospitals are made in accordance with the inpatient rehabilitation facility prospective payment system ("IRF-PPS").

**Fiscal Year 2022.** On August 4, 2021, CMS published the final rule updating policies and payment rates for the IRF-PPS for fiscal year 2022 (affecting discharges and cost reporting periods beginning on or after October 1, 2021, through September 30, 2022). The standard payment conversion factor for discharges for fiscal year 2022 was set at \$17,240, an increase from the standard payment conversion factor applicable during fiscal year 2021 of \$16,856. The update to the standard payment conversion factor for fiscal year 2022 included a market basket increase of 2.6%, less a productivity adjustment of 0.7%. CMS increased the outlier threshold amount for fiscal year 2022 to \$9,491 from \$7,906 established in the final rule for fiscal year 2021.

**Fiscal Year 2023.** On August 1, 2022, CMS published the final rule updating policies and payment rates for the IRF-PPS for fiscal year 2023 (affecting discharges and cost reporting periods beginning on or after October 1, 2022, through September 30, 2023). The standard payment conversion factor for discharges for fiscal year 2023 was set at \$17,878, an increase from the standard payment conversion factor applicable during fiscal year 2022 of \$17,240. The update to the standard payment conversion factor for fiscal year 2023 included a market basket increase of 4.2%, less a productivity adjustment of 0.3%. CMS increased the outlier threshold amount for fiscal year 2023 to \$12,526 from \$9,491 established in the final rule for fiscal year 2022.

Fiscal Year 2024. On August 2, 2023, CMS published the final rule to update policies and payment rates for the IRF-PPS for fiscal year 2024 (affecting discharges and cost reporting periods beginning on or after October 1, 2023, through September 30, 2024). Certain errors in the final rule were corrected in a document published on October 4, 2023. The standard payment conversion factor for discharges for fiscal year 2024 was set at \$18,541, an increase from the standard payment conversion factor applicable during fiscal year 2023 of \$17,878. The update to the standard payment conversion factor for fiscal year 2024 included a market basket increase of 3.6%, less a productivity adjustment of 0.2%. CMS decreased the outlier threshold amount for fiscal year 2024 to \$10,423 from \$12,526 established in the final rule for fiscal year 2023.

Fiscal Year 2025. On March 29, 2024, CMS published a proposed rule to update policies and payment rates for the IRF-PPS for fiscal year 2025 (affecting discharges and cost reporting periods beginning on or after October 1, 2024, through September 30, 2025). The standard payment conversion factor for discharges for fiscal year 2025 would be set at \$18,872, an increase from the standard payment conversion factor applicable during fiscal year 2024 of \$18,541. The update to the standard payment conversion factor for fiscal year 2025, if adopted, would include a market basket increase of 3.2%, less a productivity adjustment of 0.4%. CMS proposed to increase the outlier threshold amount for fiscal year 2025 to \$12,158 from \$10,423 established in the final rule for fiscal year 2024.

#### **Medicare Reimbursement of Outpatient Rehabilitation Clinic Services**

Our Annual Report on Form 10-K for the year ended December 31, 2023 contains a detailed discussion of Medicare reimbursement that affects our outpatient rehabilitation clinic operations in Part I — Business — Government Regulations and in Part II — Management's Discussion and Analysis of Financial Condition and Results of Operations — Regulatory Changes. Outpatient rehabilitation providers enroll in Medicare as a rehabilitation agency, a clinic, or a public health agency. The Medicare program reimburses outpatient rehabilitation providers based on the Medicare physician fee schedule. [In](#)

For calendar years 2021 and 2022, CMS's expected decreases in Medicare reimbursement were mostly offset by one-time increases in payments as a result of other legislation passed by Congress. Payments under the calendar year 2024/2023 MPFS physician fee schedule proposed rule, CMS calculated the payment rates without the 2.5% payment increase to calendar year 2023 rates from the Consolidated Appropriations Act of 2023, but with the 1.25% payment increase to calendar year 2024 rates from that legislation. As a result of the lower statutory payment increase decreased by 2%, and for calendar year 2024, and a negative 2.17% budget neutrality adjustment associated with changes to the relative value units, physician fee schedule payments are expected to decrease final CMS policies resulted in 2024. CMS expects that its proposed policies for 2024 would result in a 2% an approximate 3% decrease in Medicare payments for the therapy specialty. CMS On March 9, 2024, President Biden signed into law the Consolidated Appropriations Act, 2024, which mitigated Medicare physician payment cuts by 1.68%, resulting in a lower, 1.69% cut to payments. The full 3.37% cut was applied to payments for services provided between January 1, 2024 and the March 9, 2024 effective date. The Consolidated Appropriations Act, 2024 also proposes changes extends the Medicare physician work geographic index floor through December 31, 2024. The steps Congress has taken to reduce the quality payment program, including a transition from the Merit-Based Incentive Payment System ("MIPS") cuts to the MIPS Value Pathways ("MVPs"). First, CMS proposes revisions to the existing set of 12 MVPs that it previously adopted in the calendar year 2022 and 2023 final rules. CMS would remove certain improvement activities from these MVPs and add other quality measures for MVP participants to choose from for data reporting. CMS also proposes to consolidate two of the existing MVPs into a single primary care MVP. Finally, CMS proposed to add five new MVPs. According to CMS, the proposed Rehabilitation Support of Musculoskeletal Care MVP will be most applicable to clinicians who specialize in rehabilitation support for musculoskeletal care, including physical therapists and occupational therapists. If finalized, these new MVPs would be available for voluntary reporting Medicare physician payments for the calendar year remainder of 2024 performance period. are temporary and will not carry over into 2025.

#### **Modifiers to Identify Services of Physical Therapy Assistants or Occupational Therapy Assistants**

Our Annual Report on Form 10-K for the year ended [December 31, 2022](#) December 31, 2023, contains a detailed discussion of Medicare regulations concerning services provided by physical therapy assistants and occupational therapy assistants in Part I — Business — Government Regulations and in Part II — Management's Discussion and Analysis of Financial Condition and Results of Operations — Regulatory Changes. Since we submitted our last Annual Report on Form 10-K, CMS released the calendar year 2024 physician fee schedule proposed rule. The proposed rule does not contain any proposals concerning the modifiers for services provided by physical therapy and occupational therapy assistants. However, the proposed rule includes some potential changes There have been no significant updates to Medicare policies relating to supervision of services provided by physical therapy assistants and occupational therapy assistants. First, CMS is proposing to establish a general supervision policy for remote therapeutic monitoring services provided by physical therapy assistants and occupational therapy assistants in private practice settings. In addition, CMS is seeking comments from stakeholders regarding a potential change to the requirement for direct supervision of physical therapy assistants and occupational therapy assistants by physical therapists and occupational therapists in private practice. Specifically, CMS is considering a change to this direct supervision requirement to instead require only general supervision for all physical therapy and occupational therapy services furnished in private practice by physical therapy assistants and occupational therapy assistants, these regulations subsequently.

#### **Operating Statistics**

The following table sets forth operating statistics for each of our segments for the periods presented. The operating statistics reflect data for the period of time we managed these operations. Our operating statistics include metrics we believe provide relevant insight about the number of facilities we operate, volume of services we provide to our patients, and average payment rates for services we provide. These metrics are utilized by management to monitor trends and performance in our businesses and therefore may be important to investors because management may assess our performance based in part on such metrics. Other healthcare providers may present similar statistics, and these statistics are susceptible to varying definitions. Our statistics as presented may not be comparable to other similarly titled statistics of other companies.

Three Months Ended		Nine Months Ended		Three Months Ended March 31,	
September 30,	September 30,	September 30,	September 30,	2023	2024
2022	2023	2022	2023		

Critical illness recovery hospital data:	Critical illness recovery hospital data:	Critical illness recovery hospital data:	Critical illness recovery hospital data:
Number of consolidated hospitals—start of period <sup>(1)</sup>	Number of consolidated hospitals—start of period <sup>(1)</sup>	105	108
Number of hospitals acquired	Number of hospitals acquired	—	2
Number of hospital start-ups	Number of hospital start-ups	—	1
Number of hospitals closed/sold	Number of hospitals closed/sold	—	(1)
Number of consolidated hospitals—end of period <sup>(1)</sup>	Number of consolidated hospitals—end of period <sup>(1)</sup>	105	107
Available licensed beds <sup>(3)</sup>	Available licensed beds <sup>(3)</sup>	4,509	4,524
Available licensed beds <sup>(3)</sup>			
Available licensed beds <sup>(3)</sup>			
Admissions <sup>(3)(4)</sup>	Admissions <sup>(3)(4)</sup>	9,056	8,736
Patient days <sup>(3)</sup>	Patient days <sup>(3)</sup>	278,137	267,910
Average length of stay (days)	Average length of stay (days)	31	31
Revenue per patient day <sup>(3)(7)</sup>	Revenue per patient day <sup>(3)(7)</sup>	\$ 1,878	\$ 2,095
Occupancy rate <sup>(3)(8)</sup>	Occupancy rate <sup>(3)(8)</sup>	67 %	64 %
Percent patient days—Medicare <sup>(3)(9)</sup>	Percent patient days—Medicare <sup>(3)(9)</sup>	40 %	38 %
Rehabilitation hospital data:	Rehabilitation hospital data:	39	36
Number of consolidated hospitals—start of period <sup>(1)</sup>	Number of consolidated hospitals—start of period <sup>(1)</sup>	20	20
Number of hospitals acquired	Number of hospitals acquired	—	1
Number of hospital start-ups	Number of hospital start-ups	—	—

Number of hospitals closed/sold	Number of hospitals closed/sold	—	—	—	—
Number of consolidated hospitals—end of period <sup>(1)</sup>	Number of consolidated hospitals—end of period <sup>(1)</sup>	20	21	20	21
Number of unconsolidated hospitals managed—end of period <sup>(2)</sup>	Number of unconsolidated hospitals managed—end of period <sup>(2)</sup>	11	12	11	12
Total number of hospitals (all)—end of period	Total number of hospitals (all)—end of period	31	33	31	33
Available licensed beds <sup>(3)</sup>	Available licensed beds <sup>(3)</sup>	1,391	1,479	1,391	1,479
Admissions <sup>(3)(4)</sup>	Admissions <sup>(3)(4)</sup>	7,517	7,840	22,149	23,363
Patient days <sup>(5)</sup>	Patient days <sup>(5)</sup>	109,076	112,095	321,690	330,142
Average length of stay (days)	Average length of stay (days)	15	14	15	14
Revenue per patient day <sup>(3)(7)</sup>	Revenue per patient day <sup>(3)(7)</sup>	\$ 1,931	\$ 2,025	\$ 1,934	\$ 2,001
Occupancy rate <sup>(3)(8)</sup>	Occupancy rate <sup>(3)(8)</sup>	85 %	84 %	85 %	84 %
Percent patient days—Medicare <sup>(3)(9)</sup>	Percent patient days—Medicare <sup>(3)(9)</sup>	48 %	49 %	48 %	49 %
Outpatient rehabilitation data:	Outpatient rehabilitation data:				
Number of consolidated clinics—start of period	Number of consolidated clinics—start of period	1,599	1,638	1,572	1,622
Number of consolidated clinics—start of period	Number of consolidated clinics—start of period				
Number of clinics acquired	Number of clinics acquired	6	3	16	16
Number of clinic start-ups	Number of clinic start-ups	9	12	34	33
Number of clinics closed/sold	Number of clinics closed/sold	(5)	(8)	(13)	(26)
Number of consolidated clinics—end of period	Number of consolidated clinics—end of period	1,609	1,645	1,609	1,645

Number of unconsolidated clinics managed—	Number of unconsolidated clinics managed—			
end of period	end of period	324	301	324
Total number of clinics (all) end of period	Total number of clinics (all) end of period	1,933	1,946	1,933
Number of visits <sup>(3)(10)</sup>	Number of visits <sup>(3)(10)</sup>	2,404,868	2,627,362	7,165,866
Revenue per visit <sup>(3)(11)</sup>	Revenue per visit <sup>(3)(11)</sup>	\$ 103	\$ 100	\$ 103

	Three Months Ended		Nine Months Ended		Three Months Ended March 31,	2023	2024			
	September 30,		September 30,							
	2022	2023	2022	2023						
Concentra data:	Concentra data:									
Number of consolidated centers—start of period										
Number of consolidated centers—start of period										
Number of consolidated centers—start of period	Number of consolidated centers—start of period	518	540	518	540					
Number of centers acquired	Number of centers acquired	—	—	3	1					
Number of center start-ups	Number of center start-ups	1	—	1	—					
Number of centers closed/sold	Number of centers closed/sold	—	(1)	(3)	(2)					
Number of consolidated centers—end of period	Number of consolidated centers—end of period	519	539	519	539					
Number of onsite clinics operated—end of period	Number of onsite clinics operated—end of period	147	145	147	145					
Number of visits <sup>(3)(10)</sup>	Number of visits <sup>(3)(10)</sup>	3,273,031	3,281,042	9,604,441	9,766,881					
Number of visits <sup>(3)(10)</sup>	Number of visits <sup>(3)(10)</sup>									
Revenue per visit <sup>(3)(11)</sup>	Revenue per visit <sup>(3)(11)</sup>	\$ 128	\$ 136	\$ 127	\$ 135					

(1) Represents the number of hospitals included in our consolidated financial results at the end of each period presented.

(2) Represents the number of hospitals which are managed by us at the end of each period presented. We have minority ownership interests in these businesses.

(3) Data excludes locations managed by the Company. For purposes of our Concentra segment, onsite clinics are excluded.

(4) Represents the number of patients admitted to our hospitals during the periods presented.

(5) Each patient day represents one patient occupying one bed for one day during the periods presented.

(6) Represents the average number of days in which patients were admitted to our hospitals. Average length of stay is calculated by dividing the number of patient days, as presented above, by the number of patients discharged from our hospitals during the periods presented.

(7) Represents the average amount of revenue recognized for each patient day. Revenue per patient day is calculated by dividing patient service revenues, excluding revenues from certain other ancillary and outpatient services provided at our hospitals, by the total number of patient days.

(8) Represents the portion of our hospitals being utilized for patient care during the periods presented. Occupancy rate is calculated using the number of patient days, as presented above, divided by the total number of bed days available during the period. Bed days available is derived by adding the daily number of available licensed beds for each of the periods presented.

(9) Represents the portion of our patient days which are paid by Medicare. The Medicare patient day percentage is calculated by dividing the total number of patient days which are paid by Medicare by the total number of patient days, as presented above.

(10) Represents the number of visits in which patients were treated at our outpatient rehabilitation clinics and Concentra centers during the periods presented. **COVID-19 screening and testing services provided by our Concentra segment are not included in these figures.**

(11) Represents the average amount of revenue recognized for each patient visit. Revenue per visit is calculated by dividing patient service revenue, excluding revenues from certain other ancillary services, by the total number of visits. **For purposes of this computation for our Concentra segment, patient service revenue does not include onsite clinics or revenues generated from COVID-19 screening and testing services.**

## Results of Operations

The following table outlines selected operating data as a percentage of revenue for the periods indicated:

		Three Months		Nine Months			Three Months Ended March 31,		
		Ended		Ended			2023		
		September 30,		September 30,			2022	2023	
		2022	2023	2022	2023				
Revenue	Revenue	100.0 %	100.0 %	100.0 %	100.0 %	Revenue			
Costs and expenses:	Costs and expenses:								
Cost of services, exclusive of depreciation and amortization <sup>(1)</sup>	Cost of services, exclusive of depreciation and amortization <sup>(1)</sup>	88.9	86.6	88.2	85.6				
Cost of services, exclusive of depreciation and amortization <sup>(1)</sup>	Cost of services, exclusive of depreciation and amortization <sup>(1)</sup>								
General and administrative	General and administrative	2.5	2.5	2.4	2.5				
Depreciation and amortization	Depreciation and amortization	3.3	3.1	3.2	3.1				
Total costs and expenses	Total costs and expenses	94.7	92.2	93.8	91.2				
Other operating income	Other operating income	0.5	0.0	0.5	0.0				
Income from operations	Income from operations	5.8	7.8	6.7	8.8				
Loss on early retirement of debt	—	(0.9)	—	(0.3)					

Equity in earnings of unconsolidated subsidiaries								
Equity in earnings of unconsolidated subsidiaries								
Equity in earnings of unconsolidated subsidiaries	Equity in earnings of unconsolidated subsidiaries	0.6	0.7	0.4	0.6			
Interest expense								
Interest expense	Interest expense	(2.9)	(3.0)	(2.6)	(3.0)			
Income before income taxes	Income before income taxes	3.5	4.6	4.5	6.1			
Income tax expense	Income tax expense	1.1	0.9	1.1	1.4			
Net income	Net income	2.4	3.7	3.4	4.7			
Net income attributable to non-controlling interests	Net income attributable to non-controlling interests	0.7	0.8	0.6	0.8			
Net income attributable to Select Medical Holdings Corporation	Net income attributable to Select Medical Holdings Corporation	1.7 %	2.9 %	2.8 %	3.9 %			
							4.3 %	5.4 %

(1) Cost of services includes salaries, wages and benefits, operating supplies, lease and rent expense, and other operating costs.

The following table summarizes selected financial data by segment for the periods indicated:

		Three Months Ended September 30,			Nine Months Ended September 30,			Three Months Ended March 31,		
		2022	2023	% Change	2022	2023	% Change	2023	2024	% Change
		(in thousands, except percentages)								
Revenue:	Revenue:							Revenue:		
Critical illness recovery hospital	Critical illness recovery hospital	\$ 524,584	\$ 563,628	7.4 %	\$ 1,672,247	\$ 1,732,645	3.6 %	Critical illness recovery hospital	\$ 593,926	\$ 655,880 10.4 %
Rehabilitation hospital	Rehabilitation hospital	229,387	247,101	7.7	678,908	719,419	6.0			
Outpatient rehabilitation	Outpatient rehabilitation	284,993	291,804	2.4	844,191	890,679	5.5			
Concentra	Concentra	444,576	473,964	6.6	1,309,356	1,397,341	6.7			
Other <sup>(1)</sup>	Other <sup>(1)</sup>	84,254	89,197	5.9	247,380	265,118	7.2			
Total Company	Total Company	\$ 1,567,794	\$ 1,665,694	6.2 %	\$ 4,752,082	\$ 5,005,202	5.3 %	Total Company	\$ 1,664,980	\$ 1,788,809 7.4 %
Income (loss) from operations:	Income (loss) from operations:							Income (loss) from operations:		
Critical illness recovery hospital	Critical illness recovery hospital	\$ (5,042)	\$ 29,960	694.2 %	\$ 21,723	\$ 141,706	552.3 %	Critical illness recovery hospital	\$ 60,136	\$ 98,783 64.3 %

Rehabilitation hospital	Rehabilitation hospital	42,778	46,520	8.7	121,025	134,650	11.3						
Outpatient rehabilitation	Outpatient rehabilitation	17,558	17,485	(0.4)	61,596	63,298	2.8						
Concentra	Concentra	71,709	80,948	12.9	215,172	238,316	10.8						
Other <sup>(1)</sup>	Other <sup>(1)</sup>	(35,536)	(44,953)	N/M	(103,097)	(137,349)	N/M						
Total Company	Total Company	\$ 91,467	\$ 129,960	42.1 %	\$ 316,419	\$ 440,621	39.3 %						
Adjusted EBITDA:	Adjusted EBITDA:							Total Company	\$ 151,457	\$ 193,967	28.1	28.1	%
Critical illness recovery	Critical illness recovery							Adjusted EBITDA:					
hospital	hospital	\$ 11,013	\$ 46,362	321.0 %	\$ 66,999	\$ 188,631	181.5 %	Critical illness recovery hospital	\$ 76,773	\$ 115,940	51.0	51.0	%
Rehabilitation hospital	Rehabilitation hospital	49,772	53,626	7.7	141,996	155,531	9.5						
Outpatient rehabilitation	Outpatient rehabilitation	25,715	26,346	2.5	85,912	89,395	4.1						
Concentra	Concentra	90,025	98,907	9.9	272,101	293,046	7.7						
Other <sup>(1)</sup>	Other <sup>(1)</sup>	(23,412)	(31,404)	N/M	(69,054)	(99,234)	N/M						
Total Company	Total Company	\$ 153,113	\$ 193,837	26.6 %	\$ 497,954	\$ 627,369	26.0 %	Total Company	\$ 214,063	\$ 261,917	22.4	22.4	%
Adjusted EBITDA margins:	Adjusted EBITDA margins:							Adjusted EBITDA margins:					
Critical illness recovery	Critical illness recovery							Critical illness recovery hospital	12.9 %	17.7 %			
hospital	hospital	2.1 %	8.2 %		4.0 %	10.9 %							
Rehabilitation hospital	Rehabilitation hospital	21.7	21.7		20.9	21.6							
Outpatient rehabilitation	Outpatient rehabilitation	9.0	9.0		10.2	10.0							
Outpatient rehabilitation													
Outpatient rehabilitation													
Concentra	Concentra	20.2	20.9		20.8	21.0		Concentra	20.5	20.6	20.6		
Other <sup>(1)</sup>	Other <sup>(1)</sup>	N/M	N/M		N/M	N/M		Other <sup>(1)</sup>	N/M	N/M	N/M		
Total Company	Total Company	9.8 %	11.6 %		10.5 %	12.5 %		Total Company	12.9 %	14.6 %	14.6 %		
Total assets:	Total assets:							Total assets:					
Critical illness recovery	Critical illness recovery							Critical illness recovery hospital	\$ 2,507,265	\$ 2,608,979			
hospital	hospital	\$ 2,368,968	\$ 2,454,578		\$ 2,368,968	\$ 2,454,578							
Rehabilitation hospital	Rehabilitation hospital	1,189,486	1,222,853		1,189,486	1,222,853							
Outpatient rehabilitation	Outpatient rehabilitation	1,377,010	1,401,148		1,377,010	1,401,148							
Outpatient rehabilitation													
Outpatient rehabilitation													
Concentra	Concentra	2,309,392	2,321,671		2,309,392	2,321,671		Concentra	2,300,632	2,362,848	2,362,848		
Other <sup>(1)</sup>	Other <sup>(1)</sup>	310,120	283,758		310,120	283,758		Other <sup>(1)</sup>	290,947	228,868	228,868		
Total Company	Total Company	\$ 7,554,976	\$ 7,684,008		\$ 7,554,976	\$ 7,684,008		Total Company	\$ 7,699,736	\$ 7,858,263			

Purchases of property, equipment, and other assets:	Purchases of property, equipment, and other assets:	Purchases of property, equipment, and other assets:
Critical illness recovery	Critical illness recovery	
hospital	hospital	
	\$ 21,534	\$ 21,098
	\$ 60,631	\$ 76,119
Rehabilitation	Rehabilitation	
hospital	hospital	
	392	4,813
	11,487	15,298
Rehabilitation hospital		
Rehabilitation hospital		
Outpatient rehabilitation	Outpatient rehabilitation	
	10,098	8,855
	28,826	29,263
Concentra	Concentra	
	9,074	15,456
	28,030	45,702
Other <sup>(1)</sup>	Other <sup>(1)</sup>	
	844	(24)
	6,145	2,215
Total	Total	
Company	Company	
	\$ 41,942	\$ 50,198
	\$ 135,119	\$ 168,597
Total Company		
	\$ 58,885	\$ 52,517

(1) Other includes our corporate administration and shared services, as well as employee leasing services with our non-consolidating subsidiaries. Total assets include certain non-consolidating joint ventures and minority investments in other healthcare related businesses.

N/M — Not meaningful.

Three Months Ended **September 30, 2023** **March 31, 2024**, Compared to Three Months Ended **September 30, 2022** **March 31, 2023**

For the three months ended **September 30, 2023** **March 31, 2024**, we had revenue of **\$1,665.7 million** **\$1,788.8 million** and income from operations of **\$130.0 million** **\$194.0 million**, respectively, as compared to revenue of **\$1,567.8 million** **\$1,665.0 million** and income from operations of **\$91.5 million** **\$151.5 million** for the three months ended **September 30, 2022** **March 31, 2023**. For the three months ended **September 30, 2023** **March 31, 2024**, Adjusted EBITDA was **\$193.8 million** **\$261.9 million**, with an Adjusted EBITDA margin of **11.6%** **14.6%**, as compared to Adjusted EBITDA of **\$153.1 million** **\$214.1 million** and an Adjusted EBITDA margin of **9.8%** **12.9%** for the three months ended **September 30, 2022**, **March 31, 2023**, respectively.

A decrease in labor costs in our critical illness recovery hospital segment continued to be a significant contributor to the improvement in our financial performance as well as an increase in revenue, for the three months ended September 30, 2023 March 31, 2024, as compared to the three months ended September 30, 2022. The investments we made March 31, 2023, was the increase in the recruitment, hiring, revenue in our Critical Illness Recovery Hospital and retention of full-time staff in 2022 resulted in a significant decrease in contract labor utilization in 2023. Additionally, reduced demand in the marketplace resulted in lower contract labor rates, which further contributed to the decrease in total contract labor costs. We believe the ratio of personnel expense to net revenue for the critical illness recovery hospital segment for the three months ended September 30, 2023, is indicative of a more stabilized labor environment. Other operating income during the three months ended September 30, 2023, included \$0.5 million, compared to \$8.4 million during the three months ended September 30, 2022. Our other operating income was principally related to the recognition of payments received Rehabilitation Hospital segments, as discussed below under the Provider Relief Fund for health care related expenses and lost revenues attributable to COVID-19. **“Revenue.”**

### Revenue

**Critical Illness Recovery Hospital Segment.** Revenue increased 7.4% 10.4% to \$563.6 million \$655.9 million for the three months ended September 30, 2023 March 31, 2024, compared to \$524.6 million \$593.9 million for the three months ended September 30, 2022 March 31, 2023. The increase was due to revenue Revenue per patient day which increased 11.6% 7.8% to \$2,095 \$2,219 for the three months ended September 30, 2023 March 31, 2024, compared to \$1,878 \$2,058 for the three months ended September 30, 2022 March 31, 2023. Our patient days were 267,910 increased 2.7% to 294,622 for the three months ended March 31, 2024, compared to 286,746 days for the three months ended September 30, 2023, compared to 278,137 days for the three months ended September 30, 2022 March 31, 2023. Occupancy Occupancy in our critical illness recovery hospitals was 64% 71% and 67% 72% for the three months ended September 30, 2023 March 31, 2024 and 2022 2023, respectively.

*Rehabilitation Hospital Segment.* Revenue increased 7.7% 14.8% to \$247.1 million \$265.7 million for the three months ended September 30, 2023 March 31, 2024, compared to \$229.4 million \$231.5 million for the three months ended September 30, 2022 March 31, 2023. Our patient days increased 8.3% to 116,844 days for the three months ended March 31, 2024, compared to 107,910 days for the three months ended March 31, 2023. Revenue per patient day increased 4.9% 6.4% to \$2,025 \$2,096 for the three months ended September 30, 2023 March 31, 2024, compared to \$1,931 \$1,969 for the three months ended September 30, 2022. Our patient days increased 2.8% to 112,095 days for the three months ended September 30, 2023, compared to 109,076 days for the three months ended September 30, 2022 March 31, 2023. Occupancy in our rehabilitation hospitals was 84% 87% and 85% 86% for the three months ended September 30, 2023 March 31, 2024 and 2022 2023, respectively.

**Outpatient Rehabilitation Segment.** Revenue increased 2.4% to \$291.8 million for the three months ended September 30, 2023, compared to \$285.0 million for the three months ended September 30, 2022. The increase in revenue was due to patient visits, which increased 9.3% to 2,627,362 visits for the three months ended September 30, 2023, compared to 2,404,868 visits for the three months ended September 30, 2022. Revenue increased 2.5% to \$303.2 million for the three months ended March 31, 2024, compared to \$295.9 million for the three months ended March 31, 2023. The increase in revenue was due to patient visits, which increased 3.7% to 2,735,126 visits for the three months ended March 31, 2024, compared to 2,636,770 visits for the three months ended March 31, 2023.

ended **September 30, 2022** **March 31, 2023**. Our revenue per visit was **\$100** **\$99** for the three months ended **September 30, 2023** **March 31, 2024**, compared to **\$103** **\$101** for the three months ended **September 30, 2022**. The decrease in revenue per visit was **March 31, 2023**, principally due to a decrease in Medicare reimbursement and changes in payor mix, and an increase in variable discounts. **mix**.

**Concentra Segment.** Revenue increased **6.6%** **2.5%** to **\$474.0 million** **\$467.6 million** for the three months ended **September 30, 2023** **March 31, 2024**, compared to **\$444.6 million** **\$456.3 million** for the three months ended **September 30, 2022** **March 31, 2023**. The increase in revenue was principally due attributable to revenue per visit, which increased **6.3%** **4.5%** to **\$136** **\$139** for the three months ended **September 30, 2023** **March 31, 2024**, compared to **\$128** **\$133** for the three months ended **September 30, 2022** **March 31, 2023**. Our patient visits increased were **3,155,655** for the three months ended **March 31, 2024**, compared to **3,281,042** **3,217,945** visits for the three months ended **September 30, 2023**, compared to **3,273,031** visits for the three months ended **September 30, 2022** **March 31, 2023**.

#### **Operating Expenses**

Our operating expenses consist principally of cost of services and general and administrative expenses. Our operating expenses were **\$1,483.8 million** **\$1,543.1 million**, or **89.1%** **86.3%** of revenue, for the three months ended **September 30, 2023** **March 31, 2024**, compared to **\$1,433.3 million** **\$1,461.1 million**, or **91.4%** **87.7%** of revenue, for the three months ended **September 30, 2022** **March 31, 2023**. Our cost of services, a major component of which is labor expense, was **\$1,442.5 million** **\$1,494.6 million**, or **86.6%** **83.6%** of revenue, for the three months ended **September 30, 2023** **March 31, 2024**, compared to **\$1,393.8 million** **\$1,418.8 million**, or **88.9%** **85.2%** of revenue, for the three months ended **September 30, 2022** **March 31, 2023**. The decrease in our operating expenses relative to our revenue was principally due attributable to the decreased labor costs within an increase in revenue in our critical illness recovery hospital segment, as explained further within the "Critical Illness Recovery Hospital and Rehabilitation Hospital segments. **Adjusted EBITDA**" discussion. General and administrative expenses were **\$41.3 million** **\$48.4 million**, or **2.7%** of revenue, for the three months ended **March 31, 2024**, compared to **\$42.3 million**, or **2.5%** of revenue, for the three months ended **September 30, 2023**, compared to **\$39.5 million**, or **2.5%** **March 31, 2023**. General and administrative expenses included **\$2.3 million** of revenue, Concentra separation transaction costs for the three months ended **September 30, 2022** **March 31, 2024**.

#### **Other Operating Income**

For the three months ended **September 30, 2023** **March 31, 2024**, we had other operating income of **\$0.5 million**, compared to **\$8.4 million** for the three months ended **September 30, 2022** **\$2.3 million**. The other operating income for the three months ended **September 30, 2022**, **March 31, 2024** is principally included within the operating results of our other activities, and is principally related to the recognition of payments received under the Provider Relief Fund for health care related expenses and lost revenues attributable to COVID-19. Critical Illness Recovery Hospital segment.

#### **Adjusted EBITDA**

**Critical Illness Recovery Hospital Segment.** Adjusted EBITDA increased **321.0%** **51.0%** to **\$46.4 million** **\$115.9 million** for the three months ended **September 30, 2023** **March 31, 2024**, compared to **\$11.0 million** **\$76.8 million** for the three months ended **September 30, 2022** **March 31, 2023**. Our Adjusted EBITDA margin for the critical illness recovery hospital segment was **8.2%** **17.7%** for the three months ended **September 30, 2023** **March 31, 2024**, compared to **2.1%** **12.9%** for the three months ended **September 30, 2022** **March 31, 2023**. The increases in our Adjusted EBITDA and Adjusted EBITDA margin during the three months ended **September 30, 2023** **March 31, 2024**, as compared to the three months ended **September 30, 2022** **March 31, 2023**, were principally due to an increase in net revenue as well as a decrease in labor costs. The decrease in labor costs resulted from revenue. Additionally, our efforts in 2022 to hire additional full-time nursing staff, improve retention among our employees, and decrease our reliance on contract labor, as well as the lower contract labor rates due to reduced demand in the marketplace. Our total contract labor costs decreased by approximately **36%** **20%** during the three months year ended **September 30, 2023** **March 31, 2024**, as compared to the three months year ended **September 30, 2022**, **March 31, 2023**, which was driven by an approximate **30%** **20%** decrease in the utilization of contract registered nurses and an approximate **9%** **7%** decrease in the rate per hour for contract registered nurses.

**Rehabilitation Hospital Segment.** Adjusted EBITDA increased **7.7%** **30.0%** to **\$53.6 million** **\$61.4 million** for the three months ended **September 30, 2023** **March 31, 2024**, compared to **\$49.8 million** **\$47.2 million** for the three months ended **September 30, 2022** **March 31, 2023**. Our Adjusted EBITDA margin for the rehabilitation hospital segment was **21.7%** **23.1%** for each of the third quarters three months ended **September 30, 2023** **March 31, 2024**, and **September 30, 2022** compared to **20.4%** for the three months ended **March 31, 2023**. The increase increases in our Adjusted EBITDA was and Adjusted EBITDA margin for the three months ended **March 31, 2024**, as compared to the three months ended **March 31, 2023**, were principally due attributable to an increase in revenue.

**Outpatient Rehabilitation Segment.** Adjusted EBITDA increased **2.5%** to **\$26.3 million** was **\$24.9 million** for the three months ended **September 30, 2023** **March 31, 2024**, compared to **\$25.7 million** **\$30.2 million** for the three months ended **September 30, 2022** **March 31, 2023**. Our Adjusted EBITDA margin for the outpatient rehabilitation segment was **9.0%** **8.2%** for the three months ended **September 30, 2023** **March 31, 2024**, compared to **10.2%** for the three months ended **March 31, 2023**. The decreases in our Adjusted EBITDA and **September 30, 2022**. Adjusted EBITDA margin for the three months ended **March 31, 2024**, as compared to the three months ended **March 31, 2023**, were principally attributable due to higher labor costs, partially offset by an increase in revenue.

**Concentra Segment.** Adjusted EBITDA increased **9.9%** **2.6%** to **\$98.9 million** **\$96.1 million** for the three months ended **September 30, 2023** **March 31, 2024**, compared to **\$90.0 million** **\$93.7 million** for the three months ended **September 30, 2022** **March 31, 2023**. Our Adjusted EBITDA margin for the Concentra segment was **20.9%** **20.6%** for the three months ended **September 30, 2023** **March 31, 2024**, compared to **20.2%** **20.5%** for the three months ended **September 30, 2022** **March 31, 2023**. The increases increase in Adjusted

EBITDA and Adjusted EBITDA margin during the three months ended September 30, 2023, as compared to the three months ended September 30, 2022, were **was** principally due to an increase in revenue.

#### **Depreciation and Amortization**

Depreciation and amortization expense was **\$54.1 million** for the three months ended March 31, 2024, compared to **\$52.4 million** for the three months ended **September 30, 2023**, compared to **\$51.5 million** for the three months ended **September 30, 2022** **March 31, 2023**.

#### **Income from Operations**

For the three months ended **September 30, 2023** **March 31, 2024**, we had income from operations of **\$130.0 million** **\$194.0 million**, compared to **\$91.5 million** **\$151.5 million** for the three months ended **September 30, 2022** **March 31, 2023**. The decline in labor costs and increase in revenue experienced within our critical illness recovery hospital segment was the primary cause of the increase in income from operations is principally attributable to increases in revenue within our Critical Illness Recovery Hospital and Rehabilitation Hospital segments, as discussed above under "*Adjusted EBITDA*." Income from operations for the three months ended **September 30, 2023**, included other operating income of **\$0.5 million**, compared to **\$8.4 million** for the three months ended **September 30, 2022**, as described under "*Other Operating Income Revenue*" above.

#### **Loss on Early Retirement of Debt**

For the three months ended **September 30, 2023**, we had a loss on early retirement of debt of **\$14.7 million** related to an amendment to the Select credit agreement, as described in Note 7 - Long-Term Debt and Notes Payable.

#### **Equity in Earnings of Unconsolidated Subsidiaries**

For the three months ended **September 30, 2023** **March 31, 2024**, we had equity in earnings of unconsolidated subsidiaries of **\$11.6 million** **\$10.4 million**, compared to **\$8.1 million** **\$8.6 million** for the three months ended **September 30, 2022**. The increase in equity in earnings is principally due to the improved operating performance of our rehabilitation businesses in which we are a minority owner.

#### **Interest**

Our term loan is subject to an interest rate cap, which limits the variable interest rate index to 1.0% on \$2.0 billion of principal outstanding under the term loan. The Term SOFR rate was 5.33% at September 30, 2023, compared to the one-month LIBOR rate of 3.14% at September 30, 2022. Interest expense was \$50.3 million for the three months ended September 30, 2023, compared to \$45.2 million for the three months ended September 30, 2022. The increase in interest expense was principally due to an increase in the variable interest rate on borrowings made under our revolving credit facility.

#### **Income Taxes**

We recorded income tax expense of \$15.7 million for the three months ended September 30, 2023, which represented an effective tax rate of 20.6%. We recorded income tax expense of \$16.2 million for the three months ended September 30, 2022, which represented an effective tax rate of 29.8%. The higher effective tax rate for the three months ended September 30, 2022, resulted primarily from the effect of a change in Pennsylvania's corporate income tax rate on the net deferred tax asset.

#### **Nine Months Ended September 30, 2023, Compared to Nine Months Ended September 30, 2022**

For the nine months ended September 30, 2023, we had revenue of \$5,005.2 million and income from operations of \$440.6 million, respectively, as compared to revenue of \$4,752.1 million and income from operations of \$316.4 million for the nine months ended September 30, 2022. For the nine months ended September 30, 2023, Adjusted EBITDA was \$627.4 million, with an Adjusted EBITDA margin of 12.5%, as compared to Adjusted EBITDA of \$498.0 million and an Adjusted EBITDA margin of 10.5% for the nine months ended September 30, 2022, respectively.

A significant contributor to the improvement in our financial performance for the nine months ended September 30, 2023, compared to the nine months ended September 30, 2022, was a decrease in labor costs and an increase in revenue in our critical illness recovery hospital segment as the investments we made in the recruitment, hiring, and retention of full-time staff in 2022 resulted in a significant decrease in contract labor utilization in 2023. Additionally, reduced demand in the marketplace resulted in lower contract labor rates, which further contributed to the decrease in total contract labor costs. We believe the ratio of personnel expense to net revenue for the critical illness recovery hospital segment for the nine months ended September 30, 2023, is indicative of a more stabilized labor environment. Other operating income during the nine months ended September 30, 2023 included \$1.2 million. Other operating income during the nine months ended September 30, 2022, included \$23.6 million, principally related to the recognition of payments received under the Provider Relief Fund for health care related expenses and lost revenues attributable to COVID-19.

#### **Revenue**

**Critical Illness Recovery Hospital Segment.** Revenue increased 3.6% to \$1,732.6 million for the nine months ended September 30, 2023, compared to \$1,672.2 million for the nine months ended September 30, 2022. The increase was due to revenue per patient day, which increased 4.8% to \$2,076 for the nine months ended September 30, 2023, compared to \$1,981 for the nine months ended September 30, 2022. The increase in revenue per patient day is inclusive of the reinstatement of the 2.0% cut to Medicare payments due to sequestration. Our patient days were 831,022 for the nine months ended September 30, 2023, compared to 840,487 days for the nine months ended September 30, 2022. Occupancy in our critical illness recovery hospitals was 68% for the nine months ended September 30, 2023 and 2022.

**Rehabilitation Hospital Segment.** Revenue increased 6.0% to \$719.4 million for the nine months ended September 30, 2023, compared to \$678.9 million for the nine months ended September 30, 2022. Revenue per patient day increased 3.5% to \$2,001 for the nine months ended September 30, 2023, compared to \$1,934 for the nine months ended September 30, 2022. Our patient days increased 2.6% to 330,142 days for the nine months ended September 30, 2023, compared to 321,690 days for the nine months ended September 30, 2022. Occupancy in our rehabilitation hospitals was 84% and 85% for the nine months ended September 30, 2023 and 2022, respectively.

**Outpatient Rehabilitation Segment.** Revenue increased 5.5% to \$890.7 million for the nine months ended September 30, 2023, compared to \$844.2 million for the nine months ended September 30, 2022. The increase was due to patient visits, which increased 11.4% to 7,984,622 visits for the nine months ended September 30, 2023, compared to 7,165,866 visits for the nine months ended September 30, 2022. Our revenue per visit was \$100 for the nine months ended September 30, 2023, compared to \$103 for the nine months ended September 30, 2022, principally due to a decrease in Medicare reimbursement, changes in payor mix, and an increase in variable discounts.

**Concentra Segment.** Revenue increased 6.7% to \$1,397.3 million for the nine months ended September 30, 2023, compared to \$1,309.4 million for the nine months ended September 30, 2022. Our revenue per visit increased 6.3% to \$135 for the nine months ended September 30, 2023, compared to \$127 for the nine months ended September 30, 2022. Our patient visits increased 1.7% to 9,766,881 for the nine months ended September 30, 2023, compared to 9,604,441 visits for the nine months ended September 30, 2022. COVID-19 screening and testing services did not contribute to the Concentra segment's revenue for the nine months ended September 30, 2023, compared to \$19.3 million of revenue from these services during the nine months ended September 30, 2022.

### **Operating Expenses**

Our operating expenses consist principally of cost of services and general and administrative expenses. Our operating expenses were \$4,411.0 million, or 88.1% of revenue, for the nine months ended September 30, 2023, compared to \$4,305.6 million, or 90.6% of revenue, for the nine months ended September 30, 2022. Our cost of services, a major component of which is labor expense, was \$4,284.9 million, or 85.6% of revenue, for the nine months ended September 30, 2023, compared to \$4,191.4 million, or 88.2% of revenue, for the nine months ended September 30, 2022. The decrease in our operating expenses relative to our revenue was principally due to the decreased labor costs within our critical illness recovery hospital segment, as explained further within the "Adjusted EBITDA" discussion. General and administrative expenses were \$126.1 million, or 2.5% of revenue, for the nine months ended September 30, 2023, compared to \$114.3 million, or 2.4% of revenue, for the nine months ended September 30, 2022.

### **Other Operating Income**

For the nine months ended September 30, 2023, we had other operating income of \$1.2 million, compared to \$23.6 million for the nine months ended September 30, 2022. The other operating income for the nine months ended September 30, 2022, is included within the operating results of our other activities, and is principally related to the recognition of payments received under the Provider Relief Fund for health care related expenses and lost revenues attributable to COVID-19.

### **Adjusted EBITDA**

**Critical Illness Recovery Hospital Segment.** Adjusted EBITDA increased 181.5% to \$188.6 million for the nine months ended September 30, 2023, compared to \$67.0 million for the nine months ended September 30, 2022. Our Adjusted EBITDA margin for the critical illness recovery hospital segment was 10.9% for the nine months ended September 30, 2023, compared to 4.0% for the nine months ended September 30, 2022. The increases in our Adjusted EBITDA and Adjusted EBITDA margin during the nine months ended September 30, 2023, as compared to the nine months ended September 30, 2022, were due to lower labor costs as well as an increase in net revenue. The decrease in labor costs resulted from our efforts in 2022 to hire additional full-time nursing staff, improve retention among our employees, and decrease our reliance on contract labor, as well as the lower contract labor rates due to reduced demand in the marketplace. Our total contract labor costs decreased by approximately 65% during the nine months ended September 30, 2023, as compared to the nine months ended September 30, 2022, which was driven by an approximate 45% decrease in the utilization of contract registered nurses and an approximate 33% decrease in the rate per hour for contract registered nurses.

**Rehabilitation Hospital Segment.** Adjusted EBITDA increased 9.5% to \$155.5 million for the nine months ended September 30, 2023, compared to \$142.0 million for the nine months ended September 30, 2022. Our Adjusted EBITDA margin for the rehabilitation hospital segment was 21.6% for the nine months ended September 30, 2023, compared to 20.9% for the nine months ended September 30, 2022. The increase in Adjusted EBITDA and Adjusted EBITDA margin for the nine months ended September 30, 2023, as compared to the nine months ended September 30, 2022, was principally due to an increase in revenue.

**Outpatient Rehabilitation Segment.** Adjusted EBITDA increased 4.1% to \$89.4 million for the nine months ended September 30, 2023, compared to \$85.9 million for the nine months ended September 30, 2022. Our Adjusted EBITDA margin for the outpatient rehabilitation segment was 10.0% for the nine months ended September 30, 2023, compared to 10.2% for the nine months ended September 30, 2022.

**Concentra Segment.** Adjusted EBITDA increased 7.7% to \$293.0 million for the nine months ended September 30, 2023, compared to \$272.1 million for the nine months ended September 30, 2022. Our Adjusted EBITDA margin for the Concentra segment was 21.0% for the nine months ended September 30, 2023, compared to 20.8% for the nine months ended September 30, 2022. The increase in Adjusted EBITDA and Adjusted EBITDA margin was principally due to an increase in revenue for the nine months ended September 30, 2023, as compared to the nine months ended September 30, 2022.

### **Depreciation and Amortization**

Depreciation and amortization expense was \$154.8 million for the nine months ended September 30, 2023, compared to \$153.6 million for the nine months ended September 30, 2022.

#### Income from Operations

For the nine months ended September 30, 2023, we had income from operations of \$440.6 million, compared to \$316.4 million for the nine months ended September 30, 2022. The decline in labor costs and increase in revenue experienced within our critical illness recovery hospital segment was the primary cause of the increase in income from operations, as discussed above under "Adjusted EBITDA." Other operating income during the nine months ended September 30, 2023, was \$1.2 million, compared to \$23.6 million for the nine months ended September 30, 2022, as described under "Other Operating Income" above.

#### Loss on Early Retirement of Debt

For the nine months ended September 30, 2023, we had a loss on early retirement of debt of \$14.7 million related to an amendment to the Select credit agreement, as described in Note 7 - Long-Term Debt and Notes Payable.

#### Equity in Earnings of Unconsolidated Subsidiaries

For the nine months ended September 30, 2023, we had equity in earnings of unconsolidated subsidiaries of \$30.6 million, compared to \$19.6 million for the nine months ended September 30, 2022 March 31, 2023. The increase in equity in earnings is principally due to the improved operating performance of our rehabilitation businesses in which we are a minority owner.

#### Interest

Our term loan is subject to an interest rate cap, which limits the variable interest rate index to 1.0% on \$2.0 billion of principal outstanding under the term loan. The Term SOFR rate was 5.33% at September 30, 2023 March 31, 2024, compared to the one-month LIBOR rate of 3.14% 4.86% at September 30, 2022 March 31, 2023. Interest expense was \$147.8 million \$50.8 million for the nine three months ended September 30, 2023 March 31, 2024, compared to \$121.8 million \$48.6 million for the nine three months ended September 30, 2022 March 31, 2023. The increase in interest expense was caused by principally due to the increase in the borrowings made under borrowing spread on the revolving facility, as well as an increase in the variable interest rate term loan resulting from Amendment No. 8 to the extent not mitigated by the interest rate cap, senior secured credit agreement.

#### Income Taxes

We recorded income tax expense of \$70.8 million \$36.5 million for the nine three months ended September 30, 2023 March 31, 2024, which represented an effective tax rate of 22.9% 23.7%. We recorded income tax expense of \$54.0 million \$26.2 million for the nine three months ended September 30, 2022 March 31, 2023, which represented an effective tax rate of 25.2% 23.5%. The higher effective tax rate for the three months ended September 30, 2022, resulted primarily from the effect of a change in Pennsylvania's corporate income tax rate on the net deferred tax asset.

#### Liquidity and Capital Resources

##### Cash Flows for the Nine Three Months Ended September 30, 2023 March 31, 2024 and Nine Three Months Ended September 30, 2022 March 31, 2023

In the following, we discuss cash flows from operating activities, investing activities, and financing activities.

	Nine Months Ended		Three Months Ended March 31,		2024	
	September 30,		2023			
	2022	2023	(in thousands)	(in thousands)		
Cash flows provided by						
operating activities	\$272,281	\$402,616				
Cash flows used in						
investing activities	(169,105)	(198,893)				
Cash flows used in						
financing activities	(69,263)	(224,189)				
Net cash						
provided						
by (used						
in)						
operating						
activities						
Net cash						
used in						
investing						
activities						

Net cash	
provided	
by	
financing	
activities	
Net	Net
increase	increase
(decrease)	(decrease)
in cash	in cash
and cash	and cash
equivalents	equivalents
	33,913
	(20,466)
Cash and	Cash and
cash	cash
equivalents	equivalents
at	at
beginning	beginning
of period	of period
	74,310
	97,906
Cash and	Cash and
cash	cash
equivalents	equivalents
at end of	at end of
period	period
	\$108,223
	\$ 77,440

Operating activities provided \$402.6 million used \$66.7 million of cash flows for the nine three months ended September 30, 2023 March 31, 2024, compared to \$272.3 million \$51.4 million of cash flows provided by operating activities for the nine three months ended September 30, 2022 March 31, 2023. The cash flows from operating activities during the nine months ended September 30, 2022, included the repayment of \$82.8 million of Medicare advance payments. The remaining change in cash flows provided by operating activities year over year is principally due to an increase in accounts receivable, partially offset by an increase in net income. Our patient billing and collection processes were impacted by the cyber attack on Change Healthcare, which was a driver of the increase in our accounts receivable, in addition to the increase in revenue.

Our days sales outstanding was 58 days at March 31, 2024, compared to 52 days at September 30, 2023 December 31, 2023. Our days sales outstanding was 54 days at March 31, 2023, compared to 55 days at December 31, 2022. Our days sales outstanding was 53 days at September 30, 2022, compared to 52 days at December 31, 2021. Our days sales outstanding will fluctuate based upon variability in our collection cycles and patient volumes. The increase in our days sales outstanding at March 31, 2024 was primarily due to the impact of the Change Healthcare cybersecurity incident.

Investing activities used \$198.9 million \$57.7 million of cash flows for the nine three months ended September 30, 2023 March 31, 2024. The principal uses of cash were \$168.6 million \$52.5 million for purchases of property, equipment, and other assets, and \$30.4 million \$5.4 million for investments in and acquisitions of businesses. Investing activities used \$169.1 million \$69.1 million of cash flows for the nine three months ended September 30, 2022 March 31, 2023. The principal uses of cash were \$135.1 million \$58.9 million for purchases of property, and equipment, and \$39.4 million other assets, and \$10.2 million for investments in and acquisitions of businesses.

Financing activities used \$224.2 million provided \$133.0 million of cash flows for the nine three months ended September 30, 2023 March 31, 2024. The principal uses of cash were net repayments under our revolving facility of \$105.0 million, \$54.9 million for distributions to and purchases of non-controlling interests, and \$47.9 million of dividend payments to common stockholders. Financing activities used \$69.3 million of cash flows for the nine months ended September 30, 2022. The principal uses of cash were \$193.6 million for repurchases of common stock, \$48.7 million of dividend payments to common stockholders and \$40.7 million for distributions to and purchases of non-controlling interests. The principal source of cash was net borrowings under our revolving facility of \$220.0 million \$230.0 million. The principal uses of cash were payments of \$79.1 million on our term loan, \$16.0 million of dividend payments to common stockholders, and \$12.8 million for distributions to and purchases of non-controlling interests. Financing activities provided \$3.4 million of cash flows for the three months ended March 31, 2023. The principal source of cash was net borrowings under our revolving facility of \$15.0 million and net borrowings on our other debt of \$10.3 million. The principal uses of cash were \$15.9 million of dividend payments to common stockholders and \$8.0 million for distributions to and purchases of non-controlling interests.

### Capital Resources

**Working capital.** We had net working capital of \$110.0 million \$256.0 million at September 30, 2023 March 31, 2024, compared to \$116.2 million \$9.2 million at December 31, 2022 December 31, 2023. The increase in net working capital was principally due to an increase in accounts receivable and a decrease in our accrued expenses.

**Credit facilities.** On July 31, 2023, the Company entered into Amendment No. 8 to the Select credit agreement. Amendment No. 8 provides for a new tranche of term loans in an aggregate principal amount of \$2,103.0 million to replace the existing term loans and a \$710.0 million new revolving credit facility to replace the \$650.0 million existing revolving credit facility. The term loans and the extended revolving credit facility will mature on March 6, 2027, with an early springing maturity 90 days prior to the senior notes maturity, triggered if more than \$300.0 million of senior notes remain outstanding on May 15, 2026. The term loans have an interest rate of Term SOFR plus 3.00% and the revolving credit facility has an interest rate of Adjusted Term SOFR (which includes a 0.10% credit spread adjustment) plus 2.50%, subject to a leverage-based pricing grid. During the three months ended September 30, 2023, the Company recognized a \$14.7 million loss on early retirement of debt as a result of the amendment to the Select credit agreement.

On August 31, 2023, the Company entered into Amendment No. 9 to the Select credit agreement. Amendment No. 9 increased the revolving credit facility commitments from \$710.0 million to \$770.0 million.

At **September 30, 2023** **March 31, 2024**, Select had outstanding borrowings under its credit facilities consisting of a **\$2,097.7 million** **\$2,013.4 million** term loan (excluding unamortized original issue discounts and debt issuance costs of **\$16.5 million** **\$14.1 million**) and borrowings of **\$340.0 million** **\$510.0 million** under its revolving facility. At **September 30, 2023** **March 31, 2024**, Select had **\$374.2 million** **\$202.4 million** of availability under its revolving facility after giving effect to **\$55.8 million** **\$57.6 million** of outstanding letters of credit.

**Stock Repurchase Program.** Holdings' Board of Directors has authorized a common stock repurchase program to repurchase up to \$1.0 billion worth of shares of its common stock. **On November 2, 2023, the Board of Directors extended the common stock repurchase program from December 31, 2023, to December 31, 2025.** The common stock repurchase program will remain in effect until **then, December 31, 2025**, unless further extended or earlier terminated by the Board of Directors. Stock repurchases under this program may be made in the open market or through privately negotiated transactions, and at times and in such amounts as Holdings deems appropriate. Holdings funds this program with cash on hand and borrowings under its revolving facility. Holdings did not repurchase shares under the program during the **nine** **three** months ended **September 30, 2023** **March 31, 2024**. Since the inception of the program through **September 30, 2023** **March 31, 2024**, Holdings has repurchased 48,234,823 shares at a cost of approximately \$600.3 million, or \$12.45 per share, which includes transaction costs. The Inflation Reduction Act of 2022, which enacted a 1% excise tax on stock repurchases that exceed \$1.0 million, became effective January 1, 2023.

**Use of Capital Resources.** We may from time to time pursue opportunities to develop new joint venture relationships with large, regional health systems and other healthcare providers. We also intend to open new outpatient rehabilitation clinics and occupational health centers in local areas that we currently serve where we can benefit from existing referral relationships and brand awareness to produce incremental growth. In addition to our development activities, we may grow through opportunistic acquisitions.

#### **Liquidity**

We believe our internally generated cash flows and borrowing capacity under our revolving facility will allow us to finance our operations in both the short and long term. As of **September 30, 2023** **March 31, 2024**, we had cash and cash equivalents of **\$77.4 million** **\$92.6 million** and **\$374.2 million** **\$202.4 million** of availability under the revolving facility after giving effect to **\$340.0 million** **\$510.0 million** of outstanding borrowings and **\$55.8 million** **\$57.6 million** of outstanding letters of credit.

We may from time to time seek to retire or purchase our outstanding debt through cash purchases and/or exchanges for equity securities, in open market purchases, privately negotiated transactions, tender offers or otherwise. Such repurchases or exchanges, if any, may be funded from operating cash flows or other sources and will depend on prevailing market conditions, our liquidity requirements, contractual restrictions and other factors. The amounts involved may be material.

#### **Dividend**

On **February 16, 2023**, **May 3, 2023**, and **August 2, 2023**, our Board of Directors declared a cash dividend of \$0.125 per share. On **March 15, 2023**, **May 31, 2023**, and **September 1, 2023**, cash dividends totaling **\$15.9 million**, **\$15.9 million**, and **\$16.0 million** were paid.

On **November 2, 2023** **May 1, 2024**, our Board of Directors declared a cash dividend of \$0.125 per share. The dividend will be payable on or about **November 28, 2023**, **May 30, 2024** to stockholders of record as of the close of business on **November 15, 2023** **May 16, 2024**.

There is no assurance that future dividends will be declared. The declaration and payment of dividends in the future are at the discretion of our Board of Directors after taking into account various factors, including, but not limited to, our financial condition, operating results, available cash and current and anticipated cash needs, the terms of our indebtedness, and other factors our Board of Directors may deem to be relevant.

#### **Effects of Inflation**

The healthcare industry is labor intensive and our largest expenses are labor related costs. Wage and other expenses increase during periods of inflation and when labor shortages occur in the marketplace. We have recently experienced higher labor costs related to an inflationary environment and competitive labor market. In addition, suppliers have passed along rising costs to us in the form of higher prices. We cannot predict our ability to pass along cost increases to our customers.

#### **Recent Accounting Pronouncements**

Refer to Note 2 – Accounting Policies of the notes to our condensed consolidated financial statements included herein for information regarding recent accounting pronouncements.

### **ITEM 3. QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK**

We are subject to interest rate risk in connection with our variable rate long-term indebtedness. Our principal interest rate exposure relates to the loans outstanding under our credit facilities, which bear interest rates that are indexed against **Term SOFR**.

At **September 30, 2023** **March 31, 2024**, Select had outstanding borrowings under its credit facilities consisting of a **\$2,097.7 million** **\$2,013.4 million** term loan (excluding unamortized original issue discounts and debt issuance costs of **\$16.5 million** **\$14.1 million**) and **\$340.0 million** **\$510.0 million** of borrowings under its revolving facility.

In order to mitigate our exposure to rising interest rates, we **entered into** **have** an interest rate cap **transaction to limit our variable interest** which limits the **Term SOFR** rate to 1.0% on \$2.0 billion of principal outstanding under our term loan. The agreement applies to interest payments through September 30, 2024. As of **September 30, 2023** **March 31, 2024**, the **Term SOFR** rate was 5.33%. As of **September 30, 2023** **March 31, 2024**, **\$97.7 million** **\$13.4 million** of our term loan borrowings are subject to variable interest rates. Subsequent to the expiration of our interest rate cap on September 30, 2024, all of our term loan borrowings will be subject to variable interest rates.

As of **September 30, 2023** **March 31, 2024**, each 0.25% increase in market interest rates will impact the annual interest expense on our variable rate debt by **\$1.1 million** **\$3.8 million** per year, which includes the impact of the expiration of the interest rate cap on **September 30, 2024**.

#### ITEM 4. CONTROLS AND PROCEDURES

##### Evaluation of Disclosure Controls and Procedures

We carried out an evaluation, under the supervision and with the participation of our principal executive officer and principal financial officer, of the effectiveness of the design and operation of our disclosure controls and procedures (as defined in Rule 13a-15(e) of the Securities Exchange Act of 1934) as of the end of the period covered in this report. Based on this evaluation, as of **September 30, 2023** **March 31, 2024**, our principal executive officer and principal financial officer concluded that our disclosure controls and procedures, including the accumulation and communication of disclosure to our principal executive officer and principal financial officer as appropriate to allow timely decisions regarding disclosure, are effective to provide reasonable assurance that material information required to be included in our periodic SEC reports is recorded, processed, summarized, and reported within the time periods specified in the relevant SEC rules and forms.

##### Changes in Internal Control over Financial Reporting

There was no change in our internal control over financial reporting (as defined in Rule 13a-15(f) of the Securities Exchange Act of 1934) identified in connection with the evaluation required by Rule 13a-15(d) of the Securities Exchange Act of 1934 that occurred during the **third** **first** quarter ended **September 30, 2023** **March 31, 2024**, that has materially affected, or is reasonably likely to materially affect, our internal control over financial reporting.

##### Inherent Limitations on Effectiveness of Controls

It should be noted that any system of controls, however well designed and operated, can provide only reasonable, and not absolute, assurance that the objectives of the system will be met. In addition, the design of any control system is based in part upon certain assumptions about the likelihood of future events. Because of these and other inherent limitations of control systems, there is only reasonable assurance that our controls will succeed in achieving their goals under all potential future conditions.

## PART II: OTHER INFORMATION

#### ITEM 1. LEGAL PROCEEDINGS

Refer to the "Litigation" section contained within Note **13** **14** – Commitments and Contingencies of the notes to our condensed consolidated financial statements included herein.

#### ITEM 1A. RISK FACTORS

There have been no material changes from our risk factors set forth in our Annual Report on Form 10-K for the year ended **December 31, 2022** **December 31, 2023**.

#### ITEM 2. UNREGISTERED SALES OF EQUITY SECURITIES AND USE OF PROCEEDS

##### Purchases of Equity Securities by the Issuer

Holdings' Board of Directors authorized a common stock repurchase program to repurchase up to \$1.0 billion worth of shares of its common stock. **On November 2, 2023, the Board of Directors extended the common stock repurchase program from December 31, 2023, to December 31, 2025.** The common stock repurchase program will remain in effect until **then, December 31, 2025**, unless further extended or earlier terminated by the Board of Directors. Stock repurchases under this program may be made in the open market or through privately negotiated transactions, and at times and in such amounts as Holdings deems appropriate.

The following table provides information regarding repurchases of our common stock during **During** the three months ended **September 30, 2023**.

	Total Number of Shares Purchased	Average Price Paid Per Share	Total Number of Shares Purchased as		Approximate Dollar Value of Shares that May Yet Be Purchased Under Plans or Programs
			Part of Publicly Announced	Plans or Programs	
July 1 - July 31, 2023 <sup>(1)</sup>	244,452	\$ 30.03	—	—	\$ 399,677,961
August 1 - August 31, 2023 <sup>(1)</sup>	73,650	29.92	—	—	\$ 399,677,961
September 1 - September 30, 2023	—	—	—	—	\$ 399,677,961
<b>Total</b>	<b>318,102</b>	<b>\$ —</b>	<b>—</b>	<b>—</b>	<b>\$ 399,677,961</b>

(1) The March 31, 2024, Holdings did not repurchase shares purchased represent under the authorized common stock surrendered to us to satisfy tax withholding obligations associated with the vesting repurchase program. The common stock repurchase program has an available capacity of restricted shares issued to employees, pursuant to the provisions \$399.7 million as of our equity incentive plans. **March 31, 2024.**

#### ITEM 3. DEFAULTS UPON SENIOR SECURITIES

Not applicable.

#### ITEM 4. MINE SAFETY DISCLOSURES

Not applicable.

## ITEM 5. OTHER INFORMATION

### Rule 10b5-1 Trading Plans

During the three months ended **September 30, 2023** **March 31, 2024**, none of our directors or executive officers adopted or terminated any contract, instruction, or written plan for the purchase or sale of our securities to satisfy the affirmative defense conditions of Rule 10b5-1(c) or any non-Rule 10b5-1 trading arrangement.

### Compensation Committee Chairman

On August 2, 2023, following the resignation of Bryan C. Cressey, the Company's Board of Directors designated Daniel J. Thomas as chairman of the Compensation Committee.

## ITEM 6. EXHIBITS

Number	Description
10.1	<u>Amendment No. 8, dated as of July 31, 2023, to the Credit Agreement, dated as of March 6, 2017, by and among Select Medical Holdings Corporation, Select Medical Corporation, JPMorgan Chase Bank, N.A., as Administrative Agent and Collateral Agent, and the other lenders and issuing banks party thereto, as amended by Amendment No. 1, dated as of March 22, 2018, Amendment No. 2, dated as of October 26, 2018, Amendment No. 3, dated as of August 1, 2019, Amendment No. 4, dated as of December 10, 2019, Amendment No. 5, dated as of June 2, 2021, Amendment No. 6, dated as of February 21, 2023, and Amendment No. 7, dated as of May 31, 2023, (incorporated by reference to Exhibit 10.1 of the Current Report on Form 8-K (file No. 001-34465) filed on July 31, 2023).</u>
10.2	<u>Amendment No. 9, dated as of August 31, 2023, to the Credit Agreement, dated as of March 6, 2017, by and among Select Medical Holdings Corporation, Select Medical Corporation, JPMorgan Chase Bank, N.A., as Administrative Agent and Collateral Agent, and the other lenders and issuing banks party thereto, as amended by Amendment No. 1, dated as of March 22, 2018, Amendment No. 2, dated as of October 26, 2018, Amendment No. 3, dated as of August 1, 2019, Amendment No. 4, dated as of December 10, 2019, Amendment No. 5, dated as of June 2, 2021, Amendment No. 6, dated as of February 21, 2023, Amendment No. 7, dated as of May 31, 2023, and Amendment No. 8, dated as of July 31, 2023 (incorporated by reference to Exhibit 10.2 of the Current Report on Form 8-K (file No. 001-34465) filed on August 31, 2023).</u>
31.1	<u>Certification of Chief Executive Officer pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.</u>
31.2	<u>Certification of Executive Vice President and Chief Financial Officer pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.</u>
32.1	<u>Certification of Chief Executive Officer, and Executive Vice President and Chief Financial Officer pursuant to 18 U.S.C. Section 1350 as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.</u>
101.INS	XBRL Instance Document - the instance document does not appear in the Interactive Data File because its XBRL tags are embedded within the Inline XBRL document.
101.SCH	Inline XBRL Taxonomy Extension Schema Document.
101.CAL	Inline XBRL Taxonomy Extension Calculation Linkbase Document.
101.DEF	Inline XBRL Taxonomy Extension Definition Linkbase Document.
101.LAB	Inline XBRL Taxonomy Extension Label Linkbase Document.
101.PRE	Inline XBRL Taxonomy Extension Presentation Linkbase Document.
104	Cover Page Interactive Data File - the cover page interactive data file does not appear in the Interactive Data File because its XBRL tags are embedded within the Inline XBRL document.

## SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this Report to be signed on its behalf by the undersigned, thereunto duly authorized.

SELECT MEDICAL HOLDINGS CORPORATION

By: /s/ Michael F. Malatesta  
Michael F. Malatesta  
Executive Vice President and Chief Financial Officer  
(Duly Authorized Officer)

By: /s/ Christopher S. Weigl  
Christopher S. Weigl  
Senior Vice President, Controller & Chief Accounting Officer  
(Principal Accounting Officer)

Dated: November 2, 2023 May 2, 2024

44 36

EXHIBIT 31.1

**SELECT MEDICAL HOLDINGS CORPORATION**  
**CERTIFICATIONS PURSUANT TO SECTION 302 OF**  
**THE SARBANES-OXLEY ACT OF 2002**  
**CERTIFICATION**

I, David S. Chernow, certify that:

1. I have reviewed this quarterly report on Form 10-Q of Select Medical Holdings Corporation;
2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;
3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;
4. The registrant's other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:
  - a) Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;
  - b) Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;
  - c) Evaluated the effectiveness of the registrant's disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and
  - d) Disclosed in this report any change in the registrant's internal control over financial reporting that occurred during the registrant's most recent fiscal quarter (the registrant's fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant's internal control over financial reporting; and
5. The registrant's other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant's auditors and the audit committee of the registrant's board of directors (or persons performing the equivalent functions):
  - a) All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant's ability to record, process, summarize and report financial information; and
  - b) Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant's internal control over financial reporting.

Date: **November 2, 2023** **May 2, 2024**

*/s/* David S. Chernow

David S. Chernow

*President and Chief Executive Officer*

**EXHIBIT 31.2**

**SELECT MEDICAL HOLDINGS CORPORATION**  
**CERTIFICATIONS PURSUANT TO SECTION 302 OF**  
**THE SARBANES-OXLEY ACT OF 2002**  
**CERTIFICATION**

I, Michael F. Malatesta, certify that:

1. I have reviewed this quarterly report on Form 10-Q of Select Medical Holdings Corporation;
2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;
3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;
4. The registrant's other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:
  - a) Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;
  - b) Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;
  - c) Evaluated the effectiveness of the registrant's disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and
  - d) Disclosed in this report any change in the registrant's internal control over financial reporting that occurred during the registrant's most recent fiscal quarter (the registrant's fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant's internal control over financial reporting; and
5. The registrant's other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant's auditors and the audit committee of the registrant's board of directors (or persons performing the equivalent functions):
  - a) All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant's ability to record, process, summarize and report financial information; and
  - b) Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant's internal control over financial reporting.

Date: **November 2, 2023** **May 2, 2024**

*/s/* Michael F. Malatesta

Michael F. Malatesta

*Executive Vice President and Chief Financial Officer*

**EXHIBIT 32.1**

**CERTIFICATION PURSUANT TO**  
**18 U.S.C. SECTION 1350,**

**AS ADOPTED PURSUANT TO  
SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002**

In connection with the Quarterly Report on Form 10-Q of Select Medical Holdings Corporation (the "Company") for the period ended **September 30, 2023** **March 31, 2024** as filed with the Securities and Exchange Commission on the date hereof (the "Report"), we, David S. Chernow and Michael F. Malatesta, Chief Executive Officer and Chief Financial Officer, respectively, of the Company, certify, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that to our knowledge:

- (1) The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and
- (2) The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company as of the dates and for the periods expressed in the Report.

**November** **May 2, 2023** **2024**

/s/ David S. Chernow

David S. Chernow

*President and Chief Executive Officer*

/s/ Michael F. Malatesta

Michael F. Malatesta

*Executive Vice President and Chief Financial Officer*

#### DISCLAIMER

THE INFORMATION CONTAINED IN THE REFINITIV CORPORATE DISCLOSURES DELTA REPORT™ IS A COMPARISON OF TWO FINANCIALS PERIODIC REPORTS. THERE MAY BE MATERIAL ERRORS, OMISSIONS, OR INACCURACIES IN THE REPORT INCLUDING THE TEXT AND THE COMPARISON DATA AND TABLES. IN NO WAY DOES REFINITIV OR THE APPLICABLE COMPANY ASSUME ANY RESPONSIBILITY FOR ANY INVESTMENT OR OTHER DECISIONS MADE BASED UPON THE INFORMATION PROVIDED IN THIS REPORT. USERS ARE ADVISED TO REVIEW THE APPLICABLE COMPANY'S ACTUAL SEC FILINGS BEFORE MAKING ANY INVESTMENT OR OTHER DECISIONS.

©2024, Refinitiv. All rights reserved. Patents Pending.